<?xml version="1.0" encoding="UTF-8"?>
<svg height="870.031005859375" width="672.0029907226562" xmlns="http://www.w3.org/2000/svg">
 <g style="fill:none;">
  <path d=" M 0.05999799817800522 826.072021484375 L 22.619997024536133 826.072021484375 L 22.619997024536133 826.35546875 L 0.05999799817800522 826.35546875 Z " style="fill:none;stroke:#000000;stroke-width:1.0;"/>
  <path d=" M 33.67599868774414 837.4110107421875 L 33.959449768066406 837.4110107421875 L 33.959449768066406 860.031005859375 L 33.67599868774414 860.031005859375 Z " style="fill:none;stroke:#000000;stroke-width:1.0;"/>
  <path d=" M 627.9869995117188 837.4110107421875 L 628.2703857421875 837.4110107421875 L 628.2703857421875 860.031005859375 L 627.9869995117188 860.031005859375 Z " style="fill:none;stroke:#000000;stroke-width:1.0;"/>
  <path d=" M 639.3259887695312 826.072021484375 L 662.0029907226562 826.072021484375 L 662.0029907226562 826.35546875 L 639.3259887695312 826.35546875 Z " style="fill:none;stroke:#000000;stroke-width:1.0;"/>
  <path d=" M 639.3259887695312 33.731998443603516 L 662.0029907226562 33.731998443603516 L 662.0029907226562 34.015480041503906 L 639.3259887695312 34.015480041503906 Z " style="fill:none;stroke:#000000;stroke-width:1.0;"/>
  <path d=" M 627.9869995117188 0.0 L 628.2703857421875 0.0 L 628.2703857421875 22.677000045776367 L 627.9869995117188 22.677000045776367 Z " style="fill:none;stroke:#000000;stroke-width:1.0;"/>
  <path d=" M 33.67599868774414 0.0 L 33.959449768066406 0.0 L 33.959449768066406 22.677000045776367 L 33.67599868774414 22.677000045776367 Z " style="fill:none;stroke:#000000;stroke-width:1.0;"/>
  <path d=" M 0.05999799817800522 33.731998443603516 L 22.619997024536133 33.731998443603516 L 22.619997024536133 34.015480041503906 L 0.05999799817800522 34.015480041503906 Z " style="fill:none;stroke:#000000;stroke-width:1.0;"/>
  <text x="93.997,100.435,105.384,110.333,114.252,119.201,121.622,126.105,131.055,133.475,137.959,140.38,142.637,145.524,150.474,152.895,156.347,158.568,162.02,164.907,169.856,174.806,179.28900000000002,181.528,186.477,190.96,194.412,196.665,200.117,204.035,208.518,212.436,215.888,220.371,222.792,225.01,227.431,229.852,237.222,239.643,242.53,247.013,249.9,252.321,257.27,262.22,265.672,268.093,270.419,275.368,277.789,281.241,284.693,287.58,290.001,292.244,297.194,302.143,306.061,308.288,311.175,316.124,318.322,321.209,326.159" y="39.74800000000005" svg_rhmargin="330.077" style="fill:#171615;font-family:FHEHAC+AdvOTbc475f09;font-size:8.97px;font-style:NORMAL;font-weight:normal;">Undeniably, this study has several limitations. First, due to the</text>
  <text x="85.039,89.523,94.472,97.924,101.842,106.792,110.71,114.628,117.523,122.473,125.36,128.295,130.716,135.665,138.552,143.502,146.954,154.324,158.807,161.694,164.115,169.064,174.013,176.936,181.885,186.834,189.749,193.667,198.617,202.535,209.905,214.854,217.742,222.691,226.609,230.061,234.544,239.494,243.977,246.893,251.842,255.294,258.232,265.602,268.023,272.972,275.393,282.763,287.247,289.668,292.088,296.571,299.503,301.924,306.873,311.356,315.839,319.291,321.712,326.195" y="50.690000000000055" svg_rhmargin="330.113" style="fill:#171615;font-family:FHEHAC+AdvOTbc475f09;font-size:8.97px;font-style:NORMAL;font-weight:normal;">absence of information on chemotherapy or minimally invasive</text>
  <text x="85.039,87.927,91.379,95.297,99.78,102.667,110.038,113.956,118.905,121.792,125.12,127.541,132.49,136.408,138.829,143.779,148.728,152.646,157.595,160.892,163.313,168.262,171.55,174.437,179.386,183.304,186.63,191.113,196.529,201.945,208.38299999999998,211.631,216.58,221.064,223.951,228.434,233.383,237.867,241.319,245.237,247.658,250.974,253.395,256.282,259.734,263.05,266.968,269.856,272.743,276.661,280.579,283.466,286.747,291.697,296.646,299.956,303.408,308.358,311.81,316.293,318.714,323.197,327.68" y="61.63099999999997" svg_rhmargin="330.101" style="fill:#171615;font-family:FHEHAC+AdvOTbc475f09;font-size:8.97px;font-style:NORMAL;font-weight:normal;">treatment included in the SEER database, its effect on survival</text>
  <text x="85.039,88.958,93.907,98.857,101.277,106.226,111.741,116.69,121.64,124.527,130.052,135.001,138.919,144.395,148.314,152.797,157.28,159.701,164.65,169.133,172.021,175.939,180.888,183.309,188.841,193.325,197.243,201.161,206.111,211.06,216.009,218.42999999999998,223.933,228.416,231.868,237.425,241.90800000000002,247.403,250.855,254.773,257.661,261.113,266.062,269.514,274.463,278.382,282.3,285.187,287.608,292.091,296.009,301.543,304.995,308.914,313.397,315.818,319.27,322.157,325.609" y="72.62900000000002" svg_rhmargin="330.092" style="fill:#171615;font-family:FHEHAC+AdvOTbc475f09;font-size:8.97px;font-style:NORMAL;font-weight:normal;">could not be evaluated. Second, as a retrospective registry</text>
  <text x="85.039,89.523,92.975,96.427,100.345,103.797,107.249,114.619,118.538,123.487,126.374,128.795,130.675,133.562,138.512,140.933,144.385,146.208,149.66,152.548,157.497,162.446,166.929,168.771,173.721,178.204,181.656,183.454,186.907,191.856,199.226,203.144,204.997,207.418,212.367,215.254,218.706,221.127,226.077,229.529,231.95,235.868,237.708,242.657,246.575,249.463,253.381,257.299,260.186,263.638,265.486,270.436,273.323,275.181,279.664,281.473,284.925,288.844,291.731,295.183,300.132,303.584,308.534,312.452,316.37,319.257,321.678,326.161" y="83.57100000000003" svg_rhmargin="330.079" style="fill:#171615;font-family:FHEHAC+AdvOTbc475f09;font-size:8.97px;font-style:NORMAL;font-weight:normal;">assessment, this study has some intrinsic defects of a retrospective</text>
  <text x="85.039,88.491,91.379,96.328,101.277,105.761,108.182,110.664,116.546,121.496,123.916,127.368,132.318,134.739,137.196,142.145,147.094,151.012,153.466,156.353,161.30200000000002,163.727,166.614,171.563,175.481,177.956,180.377,185.327,192.231,194.68,197.101,202.051,205.969,208.39,213.339,217.257,222.207,226.125,230.043,232.549,234.97,239.919,242.358,246.841,251.79,256.74,261.689,266.172,268.606,275.976,279.894,284.843,287.314,294.218,296.639,299.526,304.475,306.929,311.879,315.331,319.249,323.732,327.184" y="94.51300000000003" svg_rhmargin="330.071" style="fill:#171615;font-family:FHEHAC+AdvOTbc475f09;font-size:8.97px;font-style:NORMAL;font-weight:normal;">study. Third, due to the low incidence in young men with breast</text>
  <text x="85.039,88.958,93.441,98.39,102.309,106.227,109.679,112.10000000000001,114.632,117.519,122.468,126.38600000000001,128.918,132.37,136.853,144.223,149.173,151.594,155.512,158.0,161.452,163.873,167.791,171.709,174.27,176.691,181.64000000000001,184.135,189.084,194.034,197.486,200.009,203.461,206.348,211.298,216.247,220.73000000000002,223.252,225.673,229.125,231.643,235.095,239.578,242.465,247.415,251.333,254.785,257.324,260.776,268.147,272.63,275.051,277.472,279.893,282.438,285.325,290.274,292.756,295.644,300.127,304.045,306.932,309.353,311.918,319.289,323.772,326.193" y="105.51099999999997" svg_rhmargin="330.111" style="fill:#171615;font-family:FHEHAC+AdvOTbc475f09;font-size:8.97px;font-style:NORMAL;font-weight:normal;">cancer, the sample size in our study is rather small. In fact, male</text>
  <text x="85.039,89.989,93.441,97.359,101.842,105.294,108.181,111.514,115.433,119.916,124.865,128.783,132.702,136.154,139.463,146.833,151.317,155.8,159.135,164.085,168.00300000000001,171.324,176.273,179.725,183.644,187.096,191.014,195.963,198.851,202.769,207.71800000000002,211.064,217.968,220.389,223.277,228.226,231.586,238.957,243.906,247.358,251.276,254.603,259.086,263.569,268.052,271.504,275.423,278.875,282.327,284.748,289.231,293.149,296.498,301.447,305.366,310.315,314.798,319.281,321.702,326.652" y="116.452" svg_rhmargin="330.104" style="fill:#171615;font-family:FHEHAC+AdvOTbc475f09;font-size:8.97px;font-style:NORMAL;font-weight:normal;">breast cancer may be presented with more aggressive behavior</text>
  <text x="85.039,89.523,94.472,99.42099999999999,101.197,104.084,109.033,112.95100000000001,114.803,117.224,121.707,129.077,134.027,138.976,140.768,145.717,150.667,155.616,159.53400000000002,161.346,168.717,172.635,175.522,180.005,183.457,186.344,190.827,194.279,196.7,200.152,201.993,205.445,209.928,212.816,216.734,218.547,221.999,226.482,231.431,235.915,239.833,243.285,245.078,247.965,251.417,256.367,263.737,265.544,270.493,275.442,286.18,289.067,294.016,295.817,300.767,305.716,314.683" y="127.394" svg_rhmargin="317.104" style="fill:#171615;font-family:FHEHAC+AdvOTbc475f09;font-size:8.97px;font-style:NORMAL;font-weight:normal;">and the lymph node metastasis rate ranges from 35%to 84%.</text>
  <text x="317.14,319.306,323.019" y="123.42700000000002" svg_rhmargin="326.731" style="fill:#171615;font-family:FHEHAC+AdvOTbc475f09;font-size:5.98px;font-style:NORMAL;font-weight:normal;">[29</text>
  <text x="326.778" y="123.42700000000002" svg_rhmargin="330.14" style="fill:#171615;font-family:FHEHBD+AdvOTbc475f09+20;font-size:5.98px;font-style:NORMAL;font-weight:normal;">–</text>
  <text svg_rhmargin="94.631" x="85.041,88.753,92.466,94.631" y="138.394" style="fill:#171615;font-family:FHEHAC+AdvOTbc475f09;font-size:5.98px;font-style:NORMAL;font-weight:normal;">31] </text>
  <text x="102.444,107.393,109.814,112.702,115.122,118.01,122.959,125.38,127.801,132.284,134.70499999999998,142.582,146.034,150.983,158.353,162.27100000000002,170.077,177.447,182.397,184.817,188.736,192.654,197.603,200.024,204.507,207.959,215.77,219.688,224.638,229.121,232.573,237.056,240.974,243.861,247.78,251.232,253.653,257.105,259.992,262.413,266.331,269.783,277.677,282.16,285.047,287.934,291.853,295.771,298.658,301.079,306.028,310.511,318.325,321.212,326.161" y="138.394" svg_rhmargin="330.079" style="fill:#171615;font-family:FHEHAC+AdvOTbc475f09;font-size:8.97px;font-style:NORMAL;font-weight:normal;">Pitifully, some molecular characteristics affecting the</text>
  <text x="85.04,89.989,93.441,98.39,102.874,107.823,112.772,116.224,118.645,122.097,124.61,129.559,132.446,134.927,142.297,146.781,149.202,153.12,155.62,160.569,165.052,167.939,170.36,174.278,179.228,182.115,185.567,188.104,195.008,197.429,200.316,205.26500000000001,207.719,212.669,216.121,220.039,224.522,227.974,230.861,233.4,237.319,241.802,246.751,250.67,254.588,258.04,260.498,267.402,271.321,274.773,278.69100000000003,281.247,286.197,291.146,294.033,296.497,300.98,305.93,310.413,312.834,317.317,321.235,325.154" y="149.336" svg_rhmargin="330.103" style="fill:#171615;font-family:FHEHAC+AdvOTbc475f09;font-size:8.97px;font-style:NORMAL;font-weight:normal;">prognosis of male patients with breast cancer were not analyzed</text>
  <text x="85.04,87.461,92.41,97.115,102.065,107.014,110.466,115.2,118.652,121.54,126.489,131.438,135.922,138.343,143.093,147.576,151.494,155.977,159.896,163.348,167.831,170.25199999999998,174.953,178.405,181.292,186.241,191.191,193.612,197.53,200.982,205.736,210.685,215.168,219.652,223.57,228.299,233.248,238.197,240.618,245.568,248.455,252.373,257.322,262.03,264.917,269.866,274.35,277.237,281.985,286.468,291.169,294.622,297.042,301.526,306.475" y="160.27700000000004" svg_rhmargin="308.896" style="fill:#171615;font-family:FHEHAC+AdvOTbc475f09;font-size:8.97px;font-style:NORMAL;font-weight:normal;">in our study. Several studies have pointed that a signi</text>
  <text x="308.921" y="160.27700000000004" svg_rhmargin="313.87" style="fill:#171615;font-family:FHEHBE+AdvOTbc475f09+fb;font-size:8.97px;font-style:NORMAL;font-weight:normal;">ﬁ</text>
  <text x="313.853,317.772,322.255,327.204" y="160.27700000000004" svg_rhmargin="330.091" style="fill:#171615;font-family:FHEHAC+AdvOTbc475f09;font-size:8.97px;font-style:NORMAL;font-weight:normal;">cant</text>
  <text x="85.04,89.989,94.938,102.309,107.258,111.176,114.628,116.616,121.566,124.453,126.367,131.316,135.8,138.687,141.108,145.026,149.975,152.863,156.315,158.341,161.228,168.598,173.548,177.0,179.887,182.308,186.791,188.784,194.2,200.638,207.075,213.513,218.46200000000002,220.418,227.789,232.738,235.625,240.108,242.995,245.416,250.366,255.31500000000003,257.267,262.216,267.166,270.618,273.039,275.926,278.347,282.83,286.748,289.635,291.621,296.571,300.489,304.972,308.891,311.311,316.261,321.21,325.128" y="171.21900000000005" svg_rhmargin="330.077" style="fill:#171615;font-family:FHEHAC+AdvOTbc475f09;font-size:8.97px;font-style:NORMAL;font-weight:normal;">number of patients (mostly BRCA2 mutation positive) developed</text>
  <text x="85.04,92.41,97.359,99.78,102.667,105.088,110.038,112.459,116.37700000000001,118.487,122.406,126.889,131.838,135.757,139.675,143.127,146.579,148.704,151.125,156.074,159.993,162.413,167.363,172.312,174.733,179.683,184.166,186.233,193.604,198.087,200.508,204.42600000000002,206.529,211.478,214.93,218.848,223.331,226.783,229.67,231.813,235.731,240.214,245.163,249.082,253.0,256.452,258.873,260.952,268.322,273.272,276.724,279.611,281.701,289.071,293.555,295.975,299.89300000000003,301.996,305.915,310.398,315.347,319.265,323.184,326.636" y="182.21699999999998" svg_rhmargin="330.088" style="fill:#171615;font-family:FHEHAC+AdvOTbc475f09;font-size:8.97px;font-style:NORMAL;font-weight:normal;">multiple cancers including male breast cancer; most male cancers</text>
  <text x="85.04,89.523,92.975,96.893,101.424,106.839,113.277,117.751,122.701,127.65,131.102,133.523,136.41,138.831,143.314,147.232,151.766,156.715,161.665,164.552,169.057,175.961,178.381,181.269,186.218,191.167,196.117,199.004,203.525,208.008,212.482,216.4,221.35,224.802,228.254,232.172,235.624,240.574,245.523,250.472,255.422,257.843,262.792,267.275,271.837,274.258,279.208,283.126,286.578,290.496,294.979,298.431,302.349,306.872,309.293,314.242,318.721,323.671" y="193.15800000000002" svg_rhmargin="330.109" style="fill:#171615;font-family:FHEHAC+AdvOTbc475f09;font-size:8.97px;font-style:NORMAL;font-weight:normal;">are ER positive but without a corresponding increase in PR</text>
  <text x="85.04,89.989,94.938,98.39,100.811,103.698,106.119,110.603,113.023,115.911,120.394,122.286,126.769,131.718,136.667,138.556,143.505,148.455,150.876,155.359,157.208,161.691,163.558,170.462,174.38,178.863,183.812,187.731,191.183,193.037,197.52,200.972,204.424,209.374,213.292,215.713,220.196,223.083,225.504,230.453,235.40200000000002,237.313,244.217,246.637,249.525,254.47400000000002,256.361,260.279,263.731,266.618,270.07,275.019,279.503,283.421,288.37,291.257,295.176,300.125,305.074,307.962,311.414,316.363,318.784,321.205,325.123" y="204.10000000000002" svg_rhmargin="330.072" style="fill:#171615;font-family:FHEHAC+AdvOTbc475f09;font-size:8.97px;font-style:NORMAL;font-weight:normal;">positivity and only a weaker association with estrogen-controlled</text>
  <text x="85.04,92.41,96.893,100.345,105.294,109.213,112.665,116.117,121.775,125.227,130.177,134.095,139.044,144.679,149.162,152.614,158.229,163.178,167.661,172.611,175.03199999999998,180.679,188.148,192.631,197.58,202.53,207.479,209.9,215.544,220.027,224.977,229.92600000000002,235.556,241.994,246.477,249.364,254.314,258.232,263.181,266.633,269.054,274.003,279.662,286.566,288.98699999999997,294.629,297.05,301.999,305.917,309.369,313.288,317.771,321.223,325.141" y="215.09799999999996" svg_rhmargin="330.09" style="fill:#171615;font-family:FHEHAC+AdvOTbc475f09;font-size:8.97px;font-style:NORMAL;font-weight:normal;">markers such as PS2, HSP27, and Cathepsin D; increased</text>
  <text x="85.04,92.41,96.328,99.215,104.165,108.648,111.069,115.552,118.439,120.86,125.809,130.758,133.907,138.856" y="226.03999999999996" svg_rhmargin="142.774" style="fill:#171615;font-family:FHEHAC+AdvOTbc475f09;font-size:8.97px;font-style:NORMAL;font-weight:normal;">methylation de</text>
  <text x="142.753" y="226.03999999999996" svg_rhmargin="147.702" style="fill:#171615;font-family:FHEHBE+AdvOTbc475f09+fb;font-size:8.97px;font-style:NORMAL;font-weight:normal;">ﬁ</text>
  <text x="147.742,152.691,156.61,160.062,163.162,167.645,170.702,174.154,179.103,184.053,187.505,191.423,194.31,197.46,202.409,205.296,208.402,211.289,215.772,223.142,225.563,227.984,230.405,234.888,237.309,240.432,247.802,252.285,254.706,258.62399999999997,261.747,266.697,270.149,274.067,278.55,282.002,284.889,287.995,291.914,296.397,301.346,305.264,309.183,312.635,315.717,320.201,325.15" y="226.03999999999996" svg_rhmargin="330.099" style="fill:#171615;font-family:FHEHAC+AdvOTbc475f09;font-size:8.97px;font-style:NORMAL;font-weight:normal;">nes a subset of familial male breast cancer and</text>
  <text x="85.04,91.944,94.365,97.252,102.201,107.093,111.576,116.059,119.978,123.43,127.913,132.396,136.314,141.222,148.592,152.51,155.397,160.347,164.83,167.251,171.734,174.621,177.042,181.991,186.94000000000003,191.847,194.268,199.217,204.167,208.085,213.03400000000002,217.868,225.238,229.722,234.205,239.127,244.077,247.995,252.847,257.33,262.201,267.151,270.603,274.521,277.408,282.357,284.778,289.696,294.646,298.098,303.047,307.53,312.48,317.429,320.881,323.768,326.189" y="236.981" svg_rhmargin="330.107" style="fill:#171615;font-family:FHEHAC+AdvOTbc475f09;font-size:8.97px;font-style:NORMAL;font-weight:normal;">with average methylation index may be a useful prognostic</text>
  <text x="85.04,92.41,96.893,100.345,105.294,109.213,112.665" y="247.97900000000004" svg_rhmargin="115.086" style="fill:#171615;font-family:FHEHAC+AdvOTbc475f09;font-size:8.97px;font-style:NORMAL;font-weight:normal;">marker.</text>
  <text x="115.087,117.253,120.965" y="243.95600000000002" svg_rhmargin="124.677" style="fill:#171615;font-family:FHEHAC+AdvOTbc475f09;font-size:5.98px;font-style:NORMAL;font-weight:normal;">[32</text>
  <text x="124.724" y="243.95600000000002" svg_rhmargin="128.086" style="fill:#171615;font-family:FHEHBD+AdvOTbc475f09+20;font-size:5.98px;font-style:NORMAL;font-weight:normal;">–</text>
  <text x="128.069,131.782,135.553" y="243.95600000000002" svg_rhmargin="137.718" style="fill:#171615;font-family:FHEHAC+AdvOTbc475f09;font-size:5.98px;font-style:NORMAL;font-weight:normal;">34]</text>
  <text x="93.997,96.884,101.833,103.804,106.691,111.174,115.093,117.98,120.40100000000001,122.342,125.794,130.743,138.114,142.032,143.998,148.948,151.369,154.821,159.77,164.719,167.607,171.525,174.977,176.936,180.854,185.337,190.286,192.242,197.192,201.11,203.014,207.963,210.384,213.836,217.754,222.704,227.187,231.105,234.557,238.475,243.424,245.419,249.902,254.851,259.801,264.75,267.637,269.57,272.457,277.406,281.324,283.232,288.182,291.634,296.583,301.066,306.016,310.965,314.417,316.838,320.29,322.292,327.242" y="258.923" svg_rhmargin="330.129" style="fill:#171615;font-family:FHEHAC+AdvOTbc475f09;font-size:8.97px;font-style:NORMAL;font-weight:normal;">In fact, some disputes can be discovered about the prognosis of</text>
  <text x="85.039,89.523,94.472,99.421,104.371,108.854,112.138,117.088,121.571,124.458,126.879,130.797,135.747,138.634,142.08599999999998,145.472,147.893,152.842,156.131,160.614,163.035,165.456,168.773,171.66,176.61,183.98,188.929,192.381,195.702,198.589,203.072,208.021,211.939,215.392,217.813,221.156,226.105,231.055,234.507,237.823,241.742,246.691,251.174,258.545,263.494,265.915,269.833,272.254,275.58,280.063,283.404,286.856,289.743,294.692,299.642,304.125,307.44,310.328,315.277,320.226,325.176" y="269.865" svg_rhmargin="330.125" style="fill:#171615;font-family:FHEHAC+AdvOTbc475f09;font-size:8.97px;font-style:NORMAL;font-weight:normal;">young patients in all tumor types. For example, a study found</text>
  <text x="85.039,87.927,92.876,97.359,100.246,103.181,107.664,112.147,115.599,118.486,121.938,124.359,128.277,131.186,135.105,139.588,144.537,148.455,152.374,155.826,158.738,161.159,166.108,168.999,173.482,178.432,183.381,188.33,192.81300000000002,195.701,200.65,205.133,208.02,210.441,214.36,219.309,222.196,225.648,228.582,235.952,240.902,244.354,248.27200000000002,251.202,255.685,260.168,264.652,268.104,272.022,275.474,278.926,281.347,285.83,289.748,292.169,295.08,300.03,304.979,311.883,315.802,320.285,324.203,327.655" y="280.86300000000006" svg_rhmargin="330.076" style="fill:#171615;font-family:FHEHAC+AdvOTbc475f09;font-size:8.97px;font-style:NORMAL;font-weight:normal;">that gastric cancer in young patients more aggressive; however,</text>
  <text x="85.039,88.958,93.907,96.328,101.277,104.729,108.648,112.566,115.453,119.936,122.35700000000001,125.857,129.775,134.258,139.208,143.126,147.044,150.496,153.976,158.925,163.409,168.358,171.777,176.26,179.77,184.72,188.638,191.525,194.412,198.33,201.782,205.225,210.174,213.626,218.576,223.059,228.008,232.957,236.409,239.297,241.718,245.636,249.16,251.581,256.53,259.989,264.472,269.422,274.371,279.32,283.803,287.257,292.207,296.69,299.577,301.998,305.916,310.866,313.753,317.205,320.705,325.655" y="291.804" svg_rhmargin="330.138" style="fill:#171615;font-family:FHEHAC+AdvOTbc475f09;font-size:8.97px;font-style:NORMAL;font-weight:normal;">colorectal cancer had a better prognostic in young patients by</text>
  <text x="85.039,89.523,94.472,99.421,102.309,107.258,111.176,114.628,116.957,120.409,123.296,128.245,133.195,137.678,139.973,144.923,148.841,156.211,161.161,166.11,169.562,172.449,175.901,180.384,183.272,187.19,192.139" y="302.746" svg_rhmargin="194.56" style="fill:#171615;font-family:FHEHAC+AdvOTbc475f09;font-size:8.97px;font-style:NORMAL;font-weight:normal;">another study demonstrated.</text>
  <text svg_rhmargin="215.625" x="194.627,196.793,200.505,204.218,206.034,209.747,213.46,215.625" y="302.747" style="fill:#171615;font-family:FHEHAC+AdvOTbc475f09;font-size:5.98px;font-style:NORMAL;font-weight:normal;">[35,36] </text>
  <text x="217.984,220.871,225.82000000000002,228.132,233.082,238.031,241.483,243.836,247.288,250.175,255.124,260.074,264.557,266.978,269.29,276.194,280.112,282.443,286.926,291.876,296.359,298.78,303.263,307.181,311.099,316.048,318.329,321.216,326.165" y="302.747" svg_rhmargin="330.083" style="fill:#171615;font-family:FHEHAC+AdvOTbc475f09;font-size:8.97px;font-style:NORMAL;font-weight:normal;">In our study, we analyzed the</text>
  <text x="85.039,89.988,92.409,95.297,98.184,102.102,105.554,109.472,114.422,117.309,120.074,123.992,126.413,128.834,133.783,136.204,140.123,144.606,147.027,149.78,154.263,159.213,164.162,166.901,171.851,176.334,179.221,184.171,189.12,191.541,196.49,200.973,203.394,207.312,210.043,212.93,217.413,221.331,224.219,229.168,232.62,236.072,238.842,243.325,248.274,253.223,255.905,260.855,264.307,269.256,273.739,278.689,283.638,287.09,289.511,292.963,295.702,300.652,303.539,306.304,310.787,315.737,320.686,325.635" y="313.688" svg_rhmargin="330.118" style="fill:#171615;font-family:FHEHAC+AdvOTbc475f09;font-size:8.97px;font-style:NORMAL;font-weight:normal;">different clinical and pathologic factors and prognosis of young</text>
  <text x="85.039,92.409,96.893,99.313,103.23100000000001,106.695,111.645,115.097,119.015,123.498,126.95,129.837,133.341,137.259,141.742,146.691,150.61,154.528,157.98,161.46,165.378,170.327,177.698,182.647,187.13,190.582,194.501,199.45000000000002,202.901,209.805,212.226,215.113,220.062,223.537,228.486,230.907,235.85600000000002,239.355,246.725,251.208,253.629,257.54699999999997,261.011,265.96,269.412,273.331,277.814,281.266,284.153,287.599,291.517,296.0,300.949,304.868,308.786,312.238,315.718,320.201,325.15" y="324.686" svg_rhmargin="330.099" style="fill:#171615;font-family:FHEHAC+AdvOTbc475f09;font-size:8.97px;font-style:NORMAL;font-weight:normal;">male breast cancer compared with old male breast cancer and</text>
  <text svg_rhmargin="217.206" x="85.039,89.522,94.472,99.421,104.37,108.85300000000001,111.343,114.231,118.149,125.519,130.002,132.423,136.341,138.895,143.845,147.297,151.215,155.698,159.15,162.037,164.52,168.438,172.921,177.871,181.789,185.707,189.159,191.675,194.562,199.512,202.964,205.451,208.338,213.288,217.20600000000002" y="335.628" style="fill:#171615;font-family:FHEHAC+AdvOTbc475f09;font-size:8.97px;font-style:NORMAL;font-weight:normal;">young female breast cancer for the </text>
  <text x="219.742" y="335.628" svg_rhmargin="224.691" style="fill:#171615;font-family:FHEHBE+AdvOTbc475f09+fb;font-size:8.97px;font-style:NORMAL;font-weight:normal;">ﬁ</text>
  <text x="224.674,228.126,231.578,234.465,236.976,239.863,242.284,249.654,253.572,255.993,258.518,264.956,269.905,274.854,277.397,284.767,289.716,293.168,297.086,299.563,303.015,306.933,309.354,313.273,317.756,322.239,327.188" y="335.628" svg_rhmargin="330.075" style="fill:#171615;font-family:FHEHAC+AdvOTbc475f09;font-size:8.97px;font-style:NORMAL;font-weight:normal;">rst time. And more relevant</text>
  <text x="85.039,88.491,92.409,95.861,99.78,104.263,107.715,111.633,116.583,120.501,123.953,126.991,131.474,134.926,138.844,141.787,146.736,150.654,154.573,159.522,163.44,168.39" y="346.569" svg_rhmargin="170.811" style="fill:#171615;font-family:FHEHAC+AdvOTbc475f09;font-size:8.97px;font-style:NORMAL;font-weight:normal;">researches are needed.</text>
  <text x="85.039,91.636,97.552,101.195,107.111,112.827,116.764,119.905,125.423,131.14,137.055,140.699,144.636,147.39,153.306,159.221,162.865,165.619,171.336,177.251" y="373.216" svg_rhmargin="182.475" style="fill:#171615;font-family:FHEGPI+AdvOTfbba3ace.B;font-size:9.46px;font-style:NORMAL;font-weight:normal;">Author contributions</text>
  <text svg_rhmargin="141.239" x="85.039,91.943,96.427,99.314,103.797,106.809,110.727,115.676,119.128,123.612,126.499,128.92,133.869,138.818,141.239" y="389.203" style="fill:#171615;font-family:FHIDOM+AdvOT66af078c.B;font-size:8.97px;font-style:NORMAL;font-weight:normal;">Data curation: </text>
  <text x="144.227,151.696,156.179,158.6,163.083,168.032,172.982,177.465,180.452,189.419,193.902,198.851,203.335,205.756,208.741,216.21,221.16,226.109,230.592,233.013,237.96200000000002,240.998,247.436,252.386,256.869,261.818,266.301" y="389.203" svg_rhmargin="268.722" style="fill:#171615;font-family:FHEHAC+AdvOTbc475f09;font-size:8.97px;font-style:NORMAL;font-weight:normal;">Haiyong Wang, Hongju Zhang.</text>
  <text svg_rhmargin="136.632" x="85.039,87.927,92.876,97.359,101.277,104.729,107.617,110.037,114.521,119.004,121.891,124.312,129.261,134.211,136.632" y="400.145" style="fill:#171615;font-family:FHIDOM+AdvOT66af078c.B;font-size:8.97px;font-style:NORMAL;font-weight:normal;">Investigation: </text>
  <text x="139.692,146.596,149.017,153.5,158.449,163.399,168.348,170.769,173.763,182.729,187.212,192.162,196.645" y="400.145" svg_rhmargin="199.066" style="fill:#171615;font-family:FHEHAC+AdvOTbc475f09;font-size:8.97px;font-style:NORMAL;font-weight:normal;">Xiaohui Wang.</text>
  <text svg_rhmargin="139.366" x="85.039,94.006,97.924,100.811,105.761,110.71,115.659,120.609,123.03,127.979,132.462,136.945,139.36599999999999" y="411.086" style="fill:#171615;font-family:FHIDOM+AdvOT66af078c.B;font-size:8.97px;font-style:NORMAL;font-weight:normal;">Methodology: </text>
  <text x="142.356,149.727,154.21,156.631,161.58,166.53,171.479,174.501,179.916,182.337" y="411.086" svg_rhmargin="184.758" style="fill:#171615;font-family:FHEHAC+AdvOTbc475f09;font-size:8.97px;font-style:NORMAL;font-weight:normal;">Naikun Li.</text>
  <text svg_rhmargin="121.425" x="85.039,89.523,94.472,97.359,100.246,107.15,111.633,115.085,119.004,121.42500000000001" y="422.084" style="fill:#171615;font-family:FHIDOM+AdvOT66af078c.B;font-size:8.97px;font-style:NORMAL;font-weight:normal;">Software: </text>
  <text x="124.441,131.91,136.393,138.814,143.297,148.246,153.196,157.679,160.667,169.633,174.116,179.065,183.549" y="422.084" svg_rhmargin="185.97" style="fill:#171615;font-family:FHEHAC+AdvOTbc475f09;font-size:8.97px;font-style:NORMAL;font-weight:normal;">Haiyong Wang.</text>
  <text svg_rhmargin="131.888" x="85.039,89.523,94.472,99.421,103.34,106.792,111.275,113.696,117.148,119.569,124.518,129.467,131.888" y="433.026" style="fill:#171615;font-family:FHIDOM+AdvOT66af078c.B;font-size:8.97px;font-style:NORMAL;font-weight:normal;">Supervision: </text>
  <text x="134.93,142.399,146.882,149.303,153.786,158.735,163.685,168.168,171.155,180.122,184.605,189.554,194.037" y="433.026" svg_rhmargin="196.458" style="fill:#171615;font-family:FHEHAC+AdvOTbc475f09;font-size:8.97px;font-style:NORMAL;font-weight:normal;">Haiyong Wang.</text>
  <text svg_rhmargin="127.863" x="85.039,91.477,95.96,98.381,100.802,105.752,110.235,113.122,115.543,120.492,125.442,127.863" y="443.968" style="fill:#171615;font-family:FHIDOM+AdvOT66af078c.B;font-size:8.97px;font-style:NORMAL;font-weight:normal;">Validation: </text>
  <text x="130.904,138.373,142.856,145.277,149.76,154.709,159.659,164.142,167.129,176.096,180.579,185.528,190.011" y="443.968" svg_rhmargin="192.432" style="fill:#171615;font-family:FHEHAC+AdvOTbc475f09;font-size:8.97px;font-style:NORMAL;font-weight:normal;">Haiyong Wang.</text>
  <text svg_rhmargin="114.619" x="85.039,94.006,97.458,99.879,102.766,105.187,110.136,114.619" y="454.909" style="fill:#171615;font-family:FHIDOM+AdvOT66af078c.B;font-size:8.97px;font-style:NORMAL;font-weight:normal;">Writing </text>
  <text svg_rhmargin="122.121" x="117.638,122.12100000000001" y="454.909" style="fill:#171615;font-family:FHIDON+AdvOT66af078c.B+20;font-size:8.97px;font-style:NORMAL;font-weight:normal;">– </text>
  <text svg_rhmargin="178.742" x="125.121,130.071,133.523,135.944,140.427,142.848,147.797,152.28,154.701,157.662,162.611,166.063,170.547,173.434,176.321,178.742" y="454.909" style="fill:#171615;font-family:FHIDOM+AdvOT66af078c.B;font-size:8.97px;font-style:NORMAL;font-weight:normal;">original draft: </text>
  <text x="181.758,189.128,193.611,196.032,200.982,205.931,210.88000000000002,213.902,219.318,221.739" y="454.909" svg_rhmargin="224.16" style="fill:#171615;font-family:FHEHAC+AdvOTbc475f09;font-size:8.97px;font-style:NORMAL;font-weight:normal;">Naikun Li.</text>
  <text svg_rhmargin="114.619" x="85.039,94.006,97.458,99.879,102.766,105.187,110.136,114.619" y="465.908" style="fill:#171615;font-family:FHIDOM+AdvOT66af078c.B;font-size:8.97px;font-style:NORMAL;font-weight:normal;">Writing </text>
  <text svg_rhmargin="122.121" x="117.638,122.12100000000001" y="465.908" style="fill:#171615;font-family:FHIDON+AdvOT66af078c.B+20;font-size:8.97px;font-style:NORMAL;font-weight:normal;">– </text>
  <text svg_rhmargin="193.029" x="125.121,128.573,132.492,136.975,139.396,143.314,150.218,153.183,161.584,164.579,168.497,173.446,175.867,178.754,181.175,186.125,190.608,193.029" y="465.908" style="fill:#171615;font-family:FHIDOM+AdvOT66af078c.B;font-size:8.97px;font-style:NORMAL;font-weight:normal;">review &amp; editing: </text>
  <text x="196.045,203.514,207.997,210.418,214.901,219.85,224.8,229.28300000000002,232.327,241.293,245.776,250.726,255.209" y="465.908" svg_rhmargin="257.63" style="fill:#171615;font-family:FHEHAC+AdvOTbc475f09;font-size:8.97px;font-style:NORMAL;font-weight:normal;">Haiyong Wang.</text>
  <text x="85.039,91.835,97.552,100.997,106.713,110.651,116.367,122.283,127.8,133.517" y="498.507" svg_rhmargin="138.741" style="fill:#171615;font-family:FHEGPI+AdvOTfbba3ace.B;font-size:9.46px;font-style:NORMAL;font-weight:normal;">References</text>
  <text x="89.348,91.754,95.878,98.284,101.593,105.329,107.346,110.611,114.347,117.612,119.62899999999999,121.887,127.252,129.269,131.524,137.666,141.402,143.419,146.296,150.42,154.156,158.281,162.405,166.141,172.283,174.55,180.304,182.321,184.584,187.461,190.726,196.868,200.604,202.621,204.878,210.243,212.26,214.516,219.88,223.616,227.741,231.006,234.271,237.148,239.402,242.279,244.684,248.42,250.826,252.844,255.72,258.126,260.144,263.409,266.286,268.596,272.721,276.845,280.97,285.094,287.111,289.344,294.709,300.074,302.326,307.691,311.427,315.551,318.817,322.082,324.959,327.213" y="512.9639999999999" svg_rhmargin="330.09" style="fill:#171615;font-family:FHEHAC+AdvOTbc475f09;font-size:7.47px;font-style:NORMAL;font-weight:normal;">[1] Siegel R, Naishadham D, Jemal A. Cancer statistics 2012. CA Cancer J</text>
  <text x="101.594,106.959,108.977,110.995,115.12,117.639,121.764,125.89,130.015,134.14,136.158,140.283,144.408,146.427,150.552,154.677" y="521.921" svg_rhmargin="158.801" style="fill:#171615;font-family:FHEHAC+AdvOTbc475f09;font-size:7.47px;font-style:NORMAL;font-weight:normal;">Clin 2012;62:283</text>
  <text x="158.853" y="521.921" svg_rhmargin="162.589" style="fill:#171615;font-family:FHEHBD+AdvOTbc475f09+20;font-size:7.47px;font-style:NORMAL;font-weight:normal;">–</text>
  <text x="162.595,166.72,170.845" y="521.921" svg_rhmargin="172.862" style="fill:#171615;font-family:FHEHAC+AdvOTbc475f09;font-size:7.47px;font-style:NORMAL;font-weight:normal;">98.</text>
  <text x="89.348,91.754,95.878,98.284,101.593,107.817,109.834,111.852,113.869,115.481,120.383,126.136,128.153,129.71,135.075,139.199,142.935,149.155,151.172,154.049,155.618,161.842,164.719,166.736,168.317,173.218,176.954,180.219,183.485,187.22,191.345,194.221,198.418,200.435,201.99,204.867,209.38,211.397,212.988,216.253,218.659,220.244,223.98,225.998,228.015,229.598,234.963,239.087,245.301,249.425,253.161,256.038,258.055,260.932,265.056,269.181,270.754,274.879,277.285,278.919,285.061,288.797,290.815,294.08,295.643,299.379,303.503,307.628,309.248,311.654,314.919,321.061,324.797,326.814" y="530.8779999999999" svg_rhmargin="330.079" style="fill:#171615;font-family:FHEHAC+AdvOTbc475f09;font-size:7.47px;font-style:NORMAL;font-weight:normal;">[2] Hill TD, Khamis HJ, Tyczynski JE, et al. Comparison of male and female</text>
  <text x="101.594,105.718,108.595,111.86,115.596,118.472,120.878,123.135,126.401,130.137,134.261,137.526,140.791,143.668,145.868,147.885,152.01,155.275,157.292,161.417,164.682,168.883,172.148,175.41299999999998,177.613,180.019,182.896,186.161,190.285,194.41,197.286,199.303,201.592,203.998,208.123,214.265,218.389,221.26600000000002,223.531,226.796,230.921,234.657,237.533,241.269,244.534,246.94,250.205,253.082,255.099,257.976,260.382,262.399,265.665,268.541,270.558,272.85,276.585,280.71,284.835,287.079,289.955,294.08,296.957,300.692,302.71,306.446,310.182,312.199,314.216,316.443,321.808,325.932" y="539.892" svg_rhmargin="330.056" style="fill:#171615;font-family:FHEHAC+AdvOTbc475f09;font-size:7.47px;font-style:NORMAL;font-weight:normal;">breast cancer incidence trends, tumor characteristics, and survival. Ann</text>
  <text x="101.594,106.107,110.231,112.248,116.373,119.638,125.78,127.797,131.922,133.939,136.457,140.581,144.706,148.83,152.955,154.972,159.097,163.221,165.311,169.435,173.56" y="548.8489999999999" svg_rhmargin="177.684" style="fill:#171615;font-family:FHEHAC+AdvOTbc475f09;font-size:7.47px;font-style:NORMAL;font-weight:normal;">Epidemiol 2005;15:773</text>
  <text x="177.675" y="548.8489999999999" svg_rhmargin="181.411" style="fill:#171615;font-family:FHEHBD+AdvOTbc475f09+20;font-size:7.47px;font-style:NORMAL;font-weight:normal;">–</text>
  <text x="181.417,185.542,189.667" y="548.8489999999999" svg_rhmargin="191.684" style="fill:#171615;font-family:FHEHAC+AdvOTbc475f09;font-size:7.47px;font-style:NORMAL;font-weight:normal;">80.</text>
  <text x="89.348,91.754,95.878,98.284,101.593,107.346,109.363,113.488,116.365,120.489,124.225,128.349,132.474,134.642,138.378,144.602,146.619,148.758,154.123,158.247,162.371,165.637,169.762,171.944,177.697,181.433,183.45,185.606,190.119,194.244,197.509,201.633,205.369,208.246,210.379,215.744,221.109,223.126,225.288,228.554,230.96,233.111,236.847,238.865,240.882,243.032,247.545,250.421,253.687,257.487,260.364,262.77,264.914,268.179,271.915,274.791,278.057,280.074,284.198,288.323,294.465,298.20099999999996,300.343,302.361,306.486,308.677,314.818,318.084,322.208,324.225,326.363" y="557.807" svg_rhmargin="330.099" style="fill:#171615;font-family:FHEHAC+AdvOTbc475f09;font-size:7.47px;font-style:NORMAL;font-weight:normal;">[3] Giordano SH, Cohen DS, Buzdar AU, et al. Breast carcinoma in men: a</text>
  <text x="101.594,105.718,109.842,113.967,118.091,120.109,123.845,126.251,128.268,132.392,136.517,138.923,143.047,146.783,149.66,152.925,157.05,159.585,162.462,164.868,168.992,173.191,176.927,178.944,181.41,186.775,190.511,194.635,197.901,201.166,204.043,206.58,210.704,214.829,218.953,223.078,225.095,229.219,233.344,237.468,239.486,243.61" y="566.764" svg_rhmargin="247.734" style="fill:#171615;font-family:FHEHAC+AdvOTbc475f09;font-size:7.47px;font-style:NORMAL;font-weight:normal;">population-based study. Cancer 2004;101:51</text>
  <text x="247.804" y="566.764" svg_rhmargin="251.54" style="fill:#171615;font-family:FHEHBD+AdvOTbc475f09+20;font-size:7.47px;font-style:NORMAL;font-weight:normal;">–</text>
  <text x="251.546,255.67" y="566.764" svg_rhmargin="257.687" style="fill:#171615;font-family:FHEHAC+AdvOTbc475f09;font-size:7.47px;font-style:NORMAL;font-weight:normal;">7.</text>
  <text x="89.348,91.754,95.878,98.284,101.593,105.329,109.453,112.718,114.736,117.612,120.48899999999999,122.057,127.422,129.439,131.015,134.75,138.875,142.611,146.347,150.471,154.207,158.332,159.926,165.291,172.762,174.779,176.365,181.267,185.391,188.65599999999998,190.197,193.074,195.091,197.968,199.985,204.11,207.846,209.471,211.489,215.613,218.878,220.896,225.02,228.285,232.41,235.675,238.94,240.536,244.661,247.067,248.643,254.785,258.521,260.538,263.803,265.366,269.491,272.368,275.633,279.369,282.245,284.651,286.228,289.493,293.229,297.353,300.683,303.949,306.825,308.842,310.377,314.89,317.767,321.032,324.833,327.71" y="575.721" svg_rhmargin="330.116" style="fill:#171615;font-family:FHEHAC+AdvOTbc475f09;font-size:7.47px;font-style:NORMAL;font-weight:normal;">[4] Speirs V, Shaaban AM. The rising incidence of male breast cancer. Breast</text>
  <text x="101.594,106.958,110.694,114.819,118.084,121.349,124.226,126.763,132.128,135.393,138.27,140.765,145.667,148.544,151.809,155.545,157.951,160.494,164.618,168.743,172.867,176.992,179.009,183.133,187.258,191.382,193.4,197.524,201.648" y="584.678" svg_rhmargin="205.772" style="fill:#171615;font-family:FHEHAC+AdvOTbc475f09;font-size:7.47px;font-style:NORMAL;font-weight:normal;">Cancer Res Treat 2009;115:429</text>
  <text x="205.795" y="584.678" svg_rhmargin="209.531" style="fill:#171615;font-family:FHEHBD+AdvOTbc475f09+20;font-size:7.47px;font-style:NORMAL;font-weight:normal;">–</text>
  <text x="209.536,213.662,217.787" y="584.678" svg_rhmargin="219.804" style="fill:#171615;font-family:FHEHAC+AdvOTbc475f09;font-size:7.47px;font-style:NORMAL;font-weight:normal;">30.</text>
  <text x="89.348,91.754,95.878,98.284,101.593,106.958,111.082,115.206,119.331,123.06700000000001,124.551,129.916,132.793,134.81,136.286,143.758,145.776,149.9,153.165,156.042,157.488,162.001,166.125,168.142,169.619,177.091,180.827,182.844,186.10899999999998,187.59,191.714,194.591,197.856,201.592,204.468,206.874,208.394,211.659,215.395,219.52,222.785,226.05,228.927,230.944,232.43,235.307,237.324,240.201,244.326,245.809,248.215,251.951,255.216,257.622,261.746,264.623,267.5,269.517,270.979,275.103,277.12,281.245,283.337,287.461,291.197,294.933,296.95,298.416,302.54,304.558,308.293,312.029,316.154,320.278,323.155,325.172,328.049" y="593.635" svg_rhmargin="330.066" style="fill:#171615;font-family:FHEHAC+AdvOTbc475f09;font-size:7.47px;font-style:NORMAL;font-weight:normal;">[5] Ruddy KJ, Winer EP. Male breast cancer: risk factors, biology, diagnosis,</text>
  <text x="101.594,103.999,106.876,110.141,113.877,116.283,122.425,125.69,129.815,132.22,134.237,136.797,140.533,144.657,148.782,151.253,154.129,158.254,161.13,164.866,166.955,170.691,174.816,177.692,180.569,184.693,186.711,190.835,192.852,195.356,200.722,204.846,208.971,211.513,217.655,221.78,225.045,229.169,231.186,233.679,237.803,241.927,246.052,250.176,252.194,256.318,260.443,262.532,266.658,270.782,274.906" y="602.649" svg_rhmargin="279.03" style="fill:#171615;font-family:FHEHAC+AdvOTbc475f09;font-size:7.47px;font-style:NORMAL;font-weight:normal;">treatment, and survivorship. Ann Oncol 2013;24:1434</text>
  <text x="279.041" y="602.649" svg_rhmargin="282.777" style="fill:#171615;font-family:FHEHBD+AdvOTbc475f09+20;font-size:7.47px;font-style:NORMAL;font-weight:normal;">–</text>
  <text x="282.783,286.908,291.034" y="602.649" svg_rhmargin="293.051" style="fill:#171615;font-family:FHEHAC+AdvOTbc475f09;font-size:7.47px;font-style:NORMAL;font-weight:normal;">43.</text>
  <text x="89.348,91.754,95.878,98.284,101.593,105.717,109.842,113.107,115.984,118.86,121.266,124.531,127.408,129.597,134.962,136.97899999999998,139.121,143.245,147.37,150.635,153.511,156.388,158.794,162.059,164.936,167.125,171.249,173.266,175.402,182.873,186.998,189.015,191.501,193.907,196.036,201.402,203.41899999999998,205.561,208.826,211.232,213.384,217.12,219.137,221.154,223.361,230.832,234.568,236.974,240.239,244.364,247.629,251.754,254.159,258.284,262.02,264.037,266.914,269.108,272.843,276.968,280.704,282.721,286.457,289.334,291.351,294.228,296.431,300.556,302.962,305.104,309.229,312.965,315.371,317.388,320.653,324.778,327.184" y="611.607" svg_rhmargin="330.061" style="fill:#171615;font-family:FHEHAC+AdvOTbc475f09;font-size:7.47px;font-style:NORMAL;font-weight:normal;">[6] Foerster R, Foerster F, Wulff V, et al. Matched-pair analysis of patients</text>
  <text x="101.594,107.347,109.364,111.77,115.895,117.296,119.702,122.967,129.109,132.845,134.863,138.128,139.518,143.254,147.379,151.504,152.897,159.039,162.775,164.792,168.057,169.45,173.575,176.451,179.716,183.452,186.4,188.806,190.199,193.464,197.2,201.324,204.589,207.855,210.731,212.748,214.121,217.857,219.224,222.489,226.613,232.829,236.954,240.689,243.566,247.302,249.708,251.725,255.461,258.726,260.096,263.832,267.956,271.692,273.71,277.445,280.39,282.407,285.284,287.301,288.667,293.18,300.651,306.016,307.431,312.795,316.531,320.656,323.921,327.186" y="620.564" svg_rhmargin="330.063" style="fill:#171615;font-family:FHEHAC+AdvOTbc475f09;font-size:7.47px;font-style:NORMAL;font-weight:normal;">with female and male breast cancer: a comparative analysis. BMC Cancer</text>
  <text x="101.594,105.719,109.844,113.969,118.094,120.112,124.238,128.363,130.381,134.506,138.631" y="629.521" svg_rhmargin="142.755" style="fill:#171615;font-family:FHEHAC+AdvOTbc475f09;font-size:7.47px;font-style:NORMAL;font-weight:normal;">2011;11:335</text>
  <text x="142.809" y="629.521" svg_rhmargin="146.545" style="fill:#171615;font-family:FHEHBD+AdvOTbc475f09+20;font-size:7.47px;font-style:NORMAL;font-weight:normal;">–</text>
  <text x="146.551,150.676,154.801" y="629.521" svg_rhmargin="156.818" style="fill:#171615;font-family:FHEHAC+AdvOTbc475f09;font-size:7.47px;font-style:NORMAL;font-weight:normal;">48.</text>
  <text x="89.348,91.754,95.878,98.284,101.593,107.346,111.471,114.736,117.612,119.63,121.647,124.912,129.037,131.524,134.401,136.418,138.838,144.591,147.856,150.733,154.937,159.061,162.797,166.922,171.046,174.31099999999998,176.762,182.127,184.144,186.57,189.446,192.711,195.117,197.523,200.78799999999998,203.293,209.046,213.559,215.576,218.032,221.297,223.703,226.139,229.875,231.892,233.909,236.4,240.524,244.649,248.773,251.65,254.915,257.792,260.265,263.142,267.267,270.143,273.879,275.896,279.632,283.368,285.385,287.872,291.997,296.121,298.527,301.792,305.917,312.058,315.324,318.201,320.694,323.1,327.225" y="638.4780000000001" svg_rhmargin="330.102" style="fill:#171615;font-family:FHEHAC+AdvOTbc475f09;font-size:7.47px;font-style:NORMAL;font-weight:normal;">[7] Gnerlich J, Deshpande A, Jeffe DB, et al. Poorer survival outcomes for</text>
  <text x="101.594,107.735,111.471,113.489,116.754,121.832,125.956,128.833,132.098,135.834,138.71,141.116,146.208,149.473,153.209,157.333,160.598,163.864,166.741,171.831,175.097,179.221,185.437,189.561,193.297,196.174,199.439,203.564,208.623,214.376,216.393,218.799,222.924,228.01,230.416,233.682,239.823,243.559,245.577,248.84199999999998,253.974,258.099,260.975,264.24,267.976,270.853,273.259,278.35,281.615,285.351,289.476,292.741,296.006,298.883,303.974,310.116,313.852,317.58799999999997,322.682,326.807" y="647.435" svg_rhmargin="330.072" style="fill:#171615;font-family:FHEHAC+AdvOTbc475f09;font-size:7.47px;font-style:NORMAL;font-weight:normal;">male breast cancer compared with female breast cancer may be</text>
  <text x="101.594,105.329,107.735,110.141,113.018,115.035,119.16,123.284,125.69,129.426,133.55,135.568,138.833,141.388,143.794,147.919,150.402,152.42,156.544,158.95,161.827,164.233,167.969,171.704,174.969,177.5,183.641,185.659,189.395,192.352,196.088,198.494,200.511,204.636,208.76,210.777,213.27,218.635,222.759,226.884,229.426,233.162,237.287,240.163,243.899,246.376,252.518,256.642,259.908,264.032,266.049,268.598,272.722,276.847,280.971,285.096,287.113,291.237,295.362,297.379,301.504,305.628,309.753" y="656.4490000000001" svg_rhmargin="313.877" style="fill:#171615;font-family:FHEHAC+AdvOTbc475f09;font-size:7.47px;font-style:NORMAL;font-weight:normal;">attributable to in-stage migration. Ann Surg Oncol 2011;18:1837</text>
  <text x="313.964" y="656.4490000000001" svg_rhmargin="317.7" style="fill:#171615;font-family:FHEHBD+AdvOTbc475f09+20;font-size:7.47px;font-style:NORMAL;font-weight:normal;">–</text>
  <text x="317.706,321.831,325.956" y="656.4490000000001" svg_rhmargin="327.973" style="fill:#171615;font-family:FHEHAC+AdvOTbc475f09;font-size:7.47px;font-style:NORMAL;font-weight:normal;">44.</text>
  <text x="89.348,91.754,95.878,98.284,101.593,106.958,111.083,112.704,118.457,122.582,124.59899999999999,126.253,131.618,135.353,139.478,143.214,144.847,151.071,153.948,155.965,157.602,162.968,167.093,168.714,174.08,176.097,177.785,181.05,183.45600000000002,185.098,188.834,190.852,192.869,194.509,199.874,201.483,205.608,208.484,212.609,216.345,220.469,224.594,227.47,229.876,231.894,235.159,236.856,240.592,244.717,248.453,250.47,254.206,257.082,259.1,261.97700000000003,263.613,267.737,270.14300000000003,271.776,277.918,281.654,283.672,286.937,288.613,292.737,295.614,298.879,302.615,305.491,307.897,309.531,312.796,316.532,320.656,323.921,327.187" y="665.407" svg_rhmargin="330.064" style="fill:#171615;font-family:FHEHAC+AdvOTbc475f09;font-size:7.47px;font-style:NORMAL;font-weight:normal;">[8] Yu XF, Yang HJ, Yu Y, et al. A prognostic analysis of male breast cancer</text>
  <text x="101.594,103.999,111.471,116.836,121.349,125.86200000000001,129.201,133.714,139.079,143.592,148.957,152.692,157.594,161.003,166.368,171.733,177.875,183.239,187.752,193.117,195.523,198.871,202.136,206.261,212.477,216.601,220.337,223.214,226.479,230.604,233.905,239.658,241.676,244.165,248.29,251.592,255.717,259.841,262.718,265.124,267.53,273.671,276.936,281.061,285.185,289.403,293.139,297.263,300.14,303.876,305.893,309.245,311.65,314.916,321.057,324.793,326.811" y="674.364" svg_rhmargin="330.076" style="fill:#171615;font-family:FHEHAC+AdvOTbc475f09;font-size:7.47px;font-style:NORMAL;font-weight:normal;">(MALE BREAST CANCER) compared with post-menopausal female</text>
  <text x="101.594,105.719,108.596,111.862,115.599,118.476,120.882,125.463,128.729,132.466,136.591,139.857,143.123,146.0,150.523,152.93,157.055,161.569,169.042,174.407,178.921,183.434,188.056,192.569,197.935,202.449,207.814,211.551,216.45299999999997,220.996,226.361,231.727,237.869,243.235,247.749,253.199,255.605,257.622,262.157,266.282,270.795,274.921,278.657,283.19,289.333,293.458,296.723,301.276,305.401,309.526,313.651,317.777,319.872,323.998,328.123" y="683.321" svg_rhmargin="330.14" style="fill:#171615;font-family:FHEHAC+AdvOTbc475f09;font-size:7.47px;font-style:NORMAL;font-weight:normal;">breast cancer (FEMALE BREAST CANCER). PLoS One 2015;10:</text>
  <text x="101.594,104.859,108.985,113.11,117.235,121.36,125.485,129.611,133.736" y="692.278" svg_rhmargin="135.753" style="fill:#171615;font-family:FHEHAC+AdvOTbc475f09;font-size:7.47px;font-style:NORMAL;font-weight:normal;">e0136670.</text>
  <text x="89.348,91.754,95.878,98.284,101.593,106.958,111.082,114.347,120.489,124.613,128.349,130.367,136.12,139.856,142.635,146.759,152.901,154.918,157.657,163.022,166.758,169.63500000000002,172.396,177.762,179.779,182.545,184.95,188.686,192.422,196.547,200.671,204.407,206.424,209.69,213.815,216.558,219.434,221.451,224.211,227.476,229.882,232.658,236.394,238.411,240.428,243.145,250.617,254.353,258.477,262.213,265.949,267.967,272.091,275.827,278.576,282.7,285.577,288.842,292.578,295.526,297.932,300.628,303.893,307.629,311.754,315.084,318.349,321.226,323.927,325.945" y="701.235" svg_rhmargin="330.069" style="fill:#171615;font-family:FHEHAC+AdvOTbc475f09;font-size:7.47px;font-style:NORMAL;font-weight:normal;">[9] Ademuyiwa FO, Cyr A, Ivanovich J, et al. Managing breast cancer in</text>
  <text x="101.594,105.329,109.454,113.578,117.703,121.439,124.704,127.58099999999999,130.731,136.485,140.609,146.751,150.016,154.141,156.158,159.359,162.624,166.748,170.484,172.502,174.519,177.784,181.909,185.645,188.91,191.787,195.016,198.752,202.876,207.001,210.152,213.029,217.153,219.171,223.295,225.701,227.718,231.843,235.967,238.844,240.861,244.052,248.565,251.442,254.707,258.508,261.385,263.791,266.955,272.32,276.056,280.18,283.445,286.71,289.587,292.748,295.154,300.908,305.032,308.768,312.03299999999996,315.197,322.67,325.935" y="710.193" svg_rhmargin="330.059" style="fill:#171615;font-family:FHEHAC+AdvOTbc475f09;font-size:7.47px;font-style:NORMAL;font-weight:normal;">younger women: challenges and solutions. Breast Cancer (Dove Med</text>
  <text x="101.594,105.718,108.595,111.86,114.736,117.613,120.019,122.512,126.636,130.76,134.885,139.009,141.027,145.151,147.169" y="719.207" svg_rhmargin="151.293" style="fill:#171615;font-family:FHEHAC+AdvOTbc475f09;font-size:7.47px;font-style:NORMAL;font-weight:normal;">Press) 2015;8:1</text>
  <text x="151.37" y="719.207" svg_rhmargin="155.106" style="fill:#171615;font-family:FHEHBD+AdvOTbc475f09+20;font-size:7.47px;font-style:NORMAL;font-weight:normal;">–</text>
  <text svg_rhmargin="161.254" x="155.112,159.237,161.254" y="37.76099999999997" style="fill:#171615;font-family:FHEHAC+AdvOTbc475f09;font-size:7.47px;font-style:NORMAL;font-weight:normal;">2. </text>
  <text x="345.202,347.608,351.732,355.857,358.26300000000003,361.585,364.462,368.586,372.711,376.835,379.712,383.836,387.961,389.759,395.124,401.348,403.365,405.179,410.543,414.668,416.685,419.95,424.075,425.87,429.995,434.508,436.525,438.285,442.799,444.817,448.082,451.818,455.083,457.96000000000004,459.771,465.136,467.153,468.898,471.304,475.428,478.694,480.711,484.835,488.101,492.31,495.575,498.84,500.587,504.711,507.117,508.92,513.044,515.921,519.186,522.922,525.799,528.2049999999999,529.952,533.217,536.953,541.077,544.407,547.673,550.55,552.287,558.04,560.058,562.464,566.589,568.387,572.511,574.529,577.405,579.811,583.547,587.672" y="37.76099999999997" svg_rhmargin="590.078" style="fill:#171615;font-family:FHEHAC+AdvOTbc475f09;font-size:7.47px;font-style:NORMAL;font-weight:normal;">[10] Johnson RH, Chien FL, Bleyer A. Incidence of breast cancer with distant</text>
  <text x="361.586,363.603,367.728,371.464,375.588,377.606,381.341,384.607,390.837,394.103,398.227,400.633,402.969,406.704,412.846,416.971,421.165,424.901,427.232,432.985,437.109,443.251,446.516,450.641,453.082,455.099,459.224,461.586,463.991,468.116,471.381,473.773,479.138,483.263,485.28,487.686,490.951,495.076,497.47,501.205,503.611,507.347,509.753,513.018,515.895,517.912,520.315,524.439,528.563,532.688,536.813,539.192,541.598,545.723,548.093,552.217,556.341,560.466,564.59,566.6070000000001,569.011,571.887,577.252,584.724" y="46.71799999999996" svg_rhmargin="590.089" style="fill:#171615;font-family:FHEHAC+AdvOTbc475f09;font-size:7.47px;font-style:NORMAL;font-weight:normal;">involvement among women in the United States, 1976 to 2009. JAMA</text>
  <text x="361.586,365.71,369.835,373.959,378.084,380.101,384.226,388.35,392.474,394.578,398.704,402.828" y="55.676000000000045" svg_rhmargin="406.952" style="fill:#171615;font-family:FHEHAC+AdvOTbc475f09;font-size:7.47px;font-style:NORMAL;font-weight:normal;">2013;309:800</text>
  <text x="406.94" y="55.676000000000045" svg_rhmargin="410.676" style="fill:#171615;font-family:FHEHBD+AdvOTbc475f09+20;font-size:7.47px;font-style:NORMAL;font-weight:normal;">–</text>
  <text x="410.682,414.807" y="55.676000000000045" svg_rhmargin="416.824" style="fill:#171615;font-family:FHEHAC+AdvOTbc475f09;font-size:7.47px;font-style:NORMAL;font-weight:normal;">5.</text>
  <text x="345.202,347.608,351.732,355.857,358.26300000000003,361.585,366.098,370.223,373.959,376.835,380.632,383.038,387.152,392.518,394.53499999999997,398.661,404.027,406.432,408.838,413.004,418.369,422.882,424.899,429.047,434.801,438.537,442.662,446.791,450.917,452.93399999999997,457.11,460.375,462.781,466.917,470.653,472.671,474.688,478.822,482.947,486.683,489.089,491.106,494.371,498.495,500.901,505.069,508.805,512.93,517.055,521.169,523.575,527.7,533.842,537.966,540.843,545.035,548.3,552.425,556.161,559.037,562.773,566.039,568.444,571.71,574.586,576.604,579.48,581.886,583.904,587.169" y="64.63300000000004" svg_rhmargin="590.046" style="fill:#171615;font-family:FHEHAC+AdvOTbc475f09;font-size:7.47px;font-style:NORMAL;font-weight:normal;">[11] Bharat A, Aft RL, Gao F, et al. Patient and tumor characteristics</text>
  <text x="361.586,365.322,368.199,371.075,375.2,378.465,380.482,384.218,386.624,389.889,394.014,396.393,402.146,404.163,406.653,410.778,413.059,415.077,419.201,422.466,425.418,428.683,432.419,435.295,438.56,442.685,445.032,451.174,455.298,458.175,460.581,464.316,466.334,468.351,470.757,474.493,476.891,478.908,483.033,485.394,489.13,493.255,497.379,501.504,505.24,507.56,513.313,517.437,523.579,526.844,530.969,533.353" y="73.59000000000003" svg_rhmargin="535.759" style="fill:#171615;font-family:FHEHAC+AdvOTbc475f09;font-size:7.47px;font-style:NORMAL;font-weight:normal;">associated with increased mortality in young women (</text>
  <text svg_rhmargin="541.555" x="535.802,541.5550000000001" y="73.59000000000003" style="fill:#171615;font-family:FHEGPO+AdvP4C4E51;font-size:7.47px;font-style:NORMAL;font-weight:normal;">&lt; </text>
  <text svg_rhmargin="550.854" x="543.852,547.977,550.8539999999999" y="73.59000000000003" style="fill:#171615;font-family:FHEHAC+AdvOTbc475f09;font-size:7.47px;font-style:NORMAL;font-weight:normal;">or </text>
  <text svg_rhmargin="558.265" x="553.207,558.266" y="73.59000000000003" style="fill:#171615;font-family:FHEHAB+AdvOTb0c9bf5d;font-size:7.47px;font-style:NORMAL;font-weight:normal;">= </text>
  <text x="560.634,564.758,568.883,571.235,574.971,578.236,581.972,584.849,587.725" y="73.59000000000003" svg_rhmargin="590.131" style="fill:#171615;font-family:FHEHAC+AdvOTbc475f09;font-size:7.47px;font-style:NORMAL;font-weight:normal;">40 years)</text>
  <text x="361.586,367.339,369.357,371.763,375.888,378.423,382.547,385.424,388.689,392.425,395.302,397.708,400.248,403.513,407.249,411.374,414.639,417.904,420.78,422.79699999999997,425.304,428.181,430.69,434.426,438.55,441.427,445.163,447.696,453.838,457.962,461.228,465.352,467.36899999999997,469.861,473.986,478.11,482.234,486.359,488.376,492.501,496.625,500.75,502.767,506.891,511.016" y="82.54700000000003" svg_rhmargin="515.14" style="fill:#171615;font-family:FHEHAC+AdvOTbc475f09;font-size:7.47px;font-style:NORMAL;font-weight:normal;">with breast cancer. J Surg Oncol 2009;100:248</text>
  <text x="515.223" y="82.54700000000003" svg_rhmargin="518.959" style="fill:#171615;font-family:FHEHBD+AdvOTbc475f09+20;font-size:7.47px;font-style:NORMAL;font-weight:normal;">–</text>
  <text x="518.964,523.09,527.215" y="82.54700000000003" svg_rhmargin="529.232" style="fill:#171615;font-family:FHEHAC+AdvOTbc475f09;font-size:7.47px;font-style:NORMAL;font-weight:normal;">51.</text>
  <text x="345.202,347.608,351.732,355.857,358.26300000000003,361.585,365.321,369.445,372.711,375.587,377.605,381.729,385.465,389.59,392.084,399.555,401.572,404.045,407.781,411.046,415.171,417.577,419.983,422.469,427.371,429.388,431.88,437.245,440.98,443.857,447.982,449.999,452.016,456.141,459.406,461.925,465.661,467.678,470.144,473.41,475.81600000000003,478.308,482.044,484.061,486.078,488.512,493.025,495.902,499.167,502.968,505.845,508.25100000000003,510.678,513.943,517.679,521.804,525.134,528.399,531.276,533.694,535.712,539.837,542.312,546.047,550.172,554.296,558.421,562.157,564.647,570.401,574.526,580.667,583.933,588.057" y="91.56100000000004" svg_rhmargin="590.074" style="fill:#171615;font-family:FHEHAC+AdvOTbc475f09;font-size:7.47px;font-style:NORMAL;font-weight:normal;">[12] Sheridan W, Scott T, Caroline S, et al. Breast cancer in young women:</text>
  <text x="361.586,365.71,369.446,373.182,376.447,378.309,380.715,384.84,388.10499999999996,389.988,394.112,396.989,401.113,404.849,409.035,413.159,416.036,418.442,420.459,423.724,425.588,427.605,433.747,437.871,439.889,441.906,445.171,448.907,451.313,453.331,457.56,461.684,464.56100000000004,466.403,470.528,472.934,474.793,478.918,481.794,485.06,488.795,491.672,494.07800000000003,495.995,499.26,502.996,507.12,510.385,513.65,516.5269999999999,518.386,521.263,525.387,529.512,531.918,535.653,539.778,543.043,545.92,547.864,551.129,555.254,558.989,563.114,566.85,570.115,574.24,576.095,580.219,583.955,587.22" y="100.51800000000003" svg_rhmargin="590.097" style="fill:#171615;font-family:FHEHAC+AdvOTbc475f09;font-size:7.47px;font-style:NORMAL;font-weight:normal;">have the prognostic implications of breast cancer subtypes changed over</text>
  <text x="361.586,363.992,366.009,372.151,375.416,378.681,381.257,385.77,388.647,391.912,395.648,398.524,400.93,403.422,408.787,412.523,416.647,419.912,423.177,426.05400000000003,428.591,433.956,437.221,440.098,442.594,447.496,450.372,453.638,457.374,459.78000000000003,462.322,466.447,470.571,474.695,478.82,480.837,484.962,489.086,493.21,495.228,499.352,503.477" y="109.476" svg_rhmargin="507.601" style="fill:#171615;font-family:FHEHAC+AdvOTbc475f09;font-size:7.47px;font-style:NORMAL;font-weight:normal;">time? Breast Cancer Res Treat 2014;147:617</text>
  <text x="507.683" y="109.476" svg_rhmargin="511.419" style="fill:#171615;font-family:FHEHBD+AdvOTbc475f09+20;font-size:7.47px;font-style:NORMAL;font-weight:normal;">–</text>
  <text x="511.425,515.549,519.674" y="109.476" svg_rhmargin="521.691" style="fill:#171615;font-family:FHEHAC+AdvOTbc475f09;font-size:7.47px;font-style:NORMAL;font-weight:normal;">29.</text>
  <text x="345.202,347.608,351.732,355.857,358.26300000000003,361.585,366.95,371.074,375.199,378.075,382.2,386.325,388.398,392.911,394.928,396.902,401.415,404.68,408.013,410.031,413.296,416.173,418.161,422.674,424.691,426.721,434.193,437.929,439.946,442.823,446.947,453.089,456.825,460.95,463.002,467.904,469.921,471.96,475.225,477.63100000000003,479.67,483.406,485.423,487.44,489.421,493.545,496.422,500.546,503.423,507.618,510.883,514.148,516.554,518.571,522.307,525.572,527.572,531.696,535.821,538.697,542.028,544.904,548.64,552.376,554.782,556.799,560.924,565.048,568.784,570.801,572.809,575.686,578.092,582.216,586.415" y="118.43299999999999" svg_rhmargin="590.151" style="fill:#171615;font-family:FHEHAC+AdvOTbc475f09;font-size:7.47px;font-style:NORMAL;font-weight:normal;">[13] Copson E, Eccles B, Maishman T, et al. Prospective observational study</text>
  <text x="361.586,365.71,368.116,370.033,374.157,377.034,380.299,384.035,386.912,389.318,391.291,394.556,398.292,402.416,405.681,408.947,411.824,413.739,416.145,419.022,422.287,426.023,428.429,434.57,437.836,441.96,444.366,446.335,450.459,454.584,456.989,460.255,464.379,470.521,473.786,476.663,478.59,480.996,485.121,487.998,489.928,495.294,500.659,502.571,508.324,512.449,518.671,521.936,526.061,527.968,531.704,535.44,538.705,542.83,544.748,548.872,552.997,555.403,559.527,563.652,565.553,569.289,572.554,576.29,579.166,582.043,583.977,587.713" y="127.38999999999999" svg_rhmargin="590.119" style="fill:#171615;font-family:FHEHAC+AdvOTbc475f09;font-size:7.47px;font-style:NORMAL;font-weight:normal;">of breast cancer treatment outcomes for UK women aged 18-40 years at</text>
  <text x="361.586,365.71,367.728,371.464,375.2,379.324,383.448,386.325,388.342,391.219,393.236,395.825,398.231,402.356,405.621,408.127,412.251,418.393,422.129,428.353,430.859,433.736,436.142,440.266,444.391,448.126,450.143,452.684,455.56100000000004,458.013,464.155,467.891,470.297,472.314,474.849,480.214,483.95,488.074,491.34,494.605,497.482,500.019,502.425,506.549,509.426,511.832,514.361,518.485,522.61,526.734,530.859,532.876,537.001,541.125,545.25,547.267,551.391,555.516" y="136.34699999999998" svg_rhmargin="559.64" style="fill:#171615;font-family:FHEHAC+AdvOTbc475f09;font-size:7.47px;font-style:NORMAL;font-weight:normal;">diagnosis: the POSH study. J Natl Cancer Inst 2013;105:978</text>
  <text x="559.727" y="136.34699999999998" svg_rhmargin="563.463" style="fill:#171615;font-family:FHEHBD+AdvOTbc475f09+20;font-size:7.47px;font-style:NORMAL;font-weight:normal;">–</text>
  <text x="563.469,567.594,571.719" y="136.34699999999998" svg_rhmargin="573.736" style="fill:#171615;font-family:FHEHAC+AdvOTbc475f09;font-size:7.47px;font-style:NORMAL;font-weight:normal;">88.</text>
  <text x="345.203,347.608,351.733,355.857,358.26300000000003,361.586,366.951,371.075,373.092,375.11,377.127,381.252,384.129,385.565,390.078,395.443,397.46,398.887,406.358,410.094,412.971,417.095,419.501,421.907,423.924,425.36,428.237,433.99,436.007,437.434,443.188,446.454,448.471,452.595,455.861,458.738,460.167,463.903,465.92,467.31,470.576,472.982,474.397,478.133,480.15,482.167,483.58,487.705,491.441,493.846,497.971,502.095,504.113,508.237,511.973,513.99,517.255,518.727,521.133,524.398,528.134,530.54,534.664,537.541,540.806,543.683,545.087,548.823,552.947,557.072,558.522,564.664,568.789,570.806,574.071,577.337,581.461,583.478,587.214" y="145.361" svg_rhmargin="590.091" style="fill:#171615;font-family:FHEHAC+AdvOTbc475f09;font-size:7.47px;font-style:NORMAL;font-weight:normal;">[14] Collins LC, Marotti JD, Gelber S, et al. Pathologic features and molecular</text>
  <text x="361.587,365.711,369.836,373.101,377.225,381.35,383.755,387.491,391.688,394.953,396.96,401.085,404.82099999999997,406.881,411.006,414.742,417.148,419.165,422.43,426.555,428.961,431.031,434.767,438.503,441.768,443.843,445.86,449.985,452.007,455.743,457.789,459.806,463.542,466.419,470.155,473.41999999999996,475.476,478.741,482.866,486.99,491.115,493.991,496.397,498.492,502.616,505.022,507.052,510.788,514.912,519.037,523.161,526.8969999999999,528.934,534.688,538.812,545.034,548.299,552.424,554.445,560.198,562.216,564.622,568.747,570.828,574.953,577.83,581.095,584.831,587.707" y="154.31899999999996" svg_rhmargin="590.113" style="fill:#171615;font-family:FHEHAC+AdvOTbc475f09;font-size:7.47px;font-style:NORMAL;font-weight:normal;">phenotype by patient age in a large cohort of young women with breast</text>
  <text x="361.587,364.852,368.588,372.712,375.977,379.242,382.119,384.136,386.699,391.212,394.089,397.354,401.09,403.967,406.373,408.864,414.229,417.965,422.09,425.355,428.62,431.497,434.034,439.399,442.664,445.541,448.093,452.995,455.872,459.137,462.873,465.279,467.765,471.889,476.013,480.138,484.262,486.28,490.404,494.529,498.653,500.67,504.795,508.919,513.044" y="163.27599999999995" svg_rhmargin="517.168" style="fill:#171615;font-family:FHEHAC+AdvOTbc475f09;font-size:7.47px;font-style:NORMAL;font-weight:normal;">cancer. Breast Cancer Res Treat 2012;131:1061</text>
  <text x="517.265" y="163.27599999999995" svg_rhmargin="521.001" style="fill:#171615;font-family:FHEHBD+AdvOTbc475f09+20;font-size:7.47px;font-style:NORMAL;font-weight:normal;">–</text>
  <text x="521.006,525.131" y="163.27599999999995" svg_rhmargin="527.148" style="fill:#171615;font-family:FHEHAC+AdvOTbc475f09;font-size:7.47px;font-style:NORMAL;font-weight:normal;">6.</text>
  <text x="345.203,347.609,351.734,355.86,358.266,361.588,365.325,369.45,372.327,376.064,379.33,381.348,383.366,385.384,389.201,393.326,396.592,399.858,401.875,405.019,409.533,413.658,415.676,419.802,423.068,429.286,431.304,435.429,437.447,441.572,445.309,449.046,451.063,454.233,457.97,462.095,466.22,469.371,473.885,478.01,482.135,485.302,490.668,493.934,496.811,501.007,503.026,505.432,508.309,511.496,513.903,517.64,522.153,526.667,532.033,534.439,537.633,541.759,544.636,548.761,552.498,555.375,559.112,565.254,568.42,570.827,576.581,582.335,588.089" y="172.23299999999995" svg_rhmargin="590.106" style="fill:#171615;font-family:FHEHAC+AdvOTbc475f09;font-size:7.47px;font-style:NORMAL;font-weight:normal;">[15] Surveillance, Epidemiology, and End Results (SEER) Program (www.</text>
  <text x="361.587,364.463,367.728,370.994,373.87,375.888,379.153,382.889,387.096,390.361,393.626,396.503,398.521,402.256,406.381,410.117,412.523,417.878,421.614,426.127,430.64" y="181.19000000000005" svg_rhmargin="436.005" style="fill:#171615;font-family:FHEHAC+AdvOTbc475f09;font-size:7.47px;font-style:NORMAL;font-weight:normal;">seer.cancer.gov) SEER</text>
  <text x="436.081" y="179.20600000000002" svg_rhmargin="439.966" style="fill:#171615;font-family:FHEGPL+AdvOTb0c9bf5d+22;font-size:7.47px;font-style:NORMAL;font-weight:normal;">∗</text>
  <text x="439.935,443.671,446.077,449.813,452.219,457.622,463.376,467.112,469.518,473.253,477.378,481.114,483.99,487.256,489.27299999999997,494.697,497.103,501.227,504.492,506.51,510.634,513.899,518.024,521.289,524.554,529.957,532.3629999999999,537.724,541.46,545.973,550.486,555.851,561.25,565.375,569.5,574.856,580.221,583.486,587.222" y="181.19000000000005" svg_rhmargin="590.099" style="fill:#171615;font-family:FHEHAC+AdvOTbc475f09;font-size:7.47px;font-style:NORMAL;font-weight:normal;">Stat Database: Incidence - SEER 18 Regs</text>
  <text x="361.586,366.951,370.216,373.092,376.358,380.094,382.97,386.235,390.36,393.898,399.652,403.388,405.794,409.53,413.059,417.184,420.712,426.937,431.062,433.938,436.815,438.832,442.097,445.833,449.958,453.223,456.767,462.132,465.868,468.274,471.151,473.168,477.293,481.029,484.602,487.007,493.149,497.274,501.01,504.275,506.681,509.946,514.071,517.594,522.107,526.231,530.356,532.373,535.25,537.267,541.003,545.201,548.937,552.401,557.765,561.501,564.378,567.643,570.597,572.614,576.097,582.239,586.363" y="190.14700000000005" svg_rhmargin="590.099" style="fill:#171615;font-family:FHEHAC+AdvOTbc475f09;font-size:7.47px;font-style:NORMAL;font-weight:normal;">Research Data + Hurricane Katrina Impacted Louisiana Cases, Nov</text>
  <text x="361.586,365.711,369.836,373.961,378.086,380.636,384.373,388.498,392.623,395.15,397.557,401.682,405.807,409.932" y="199.10500000000002" svg_rhmargin="414.056" style="fill:#171615;font-family:FHEHAC+AdvOTbc475f09;font-size:7.47px;font-style:NORMAL;font-weight:normal;">2014 Sub (1973</text>
  <text x="414.084" y="199.10500000000002" svg_rhmargin="417.82" style="fill:#171615;font-family:FHEHBD+AdvOTbc475f09+20;font-size:7.47px;font-style:NORMAL;font-weight:normal;">–</text>
  <text x="417.825,421.95,426.074,430.199,434.324,436.873,440.609,444.345,447.222,450.958,452.975,457.167,460.903,463.309,465.841,468.247,470.774,475.287,477.305,481.429,485.553,488.819,492.944,495.49,500.392,504.517,507.055,512.42,516.544,520.669,524.793,527.199,530.935,533.528,538.893,541.299,543.705,546.582,548.599,552.724,556.848,559.254,562.519,565.396,567.995,570.401,572.927,577.83,581.954,584.36,588.096" y="199.10500000000002" svg_rhmargin="590.113" style="fill:#171615;font-family:FHEHAC+AdvOTbc475f09;font-size:7.47px;font-style:NORMAL;font-weight:normal;">2012 varying) - Linked To County Attributes - Total</text>
  <text x="361.587,366.952,370.689,372.706,375.647,379.772,383.897,388.023" y="208.11900000000003" svg_rhmargin="392.147" style="fill:#171615;font-family:FHEHAC+AdvOTbc475f09;font-size:7.47px;font-style:NORMAL;font-weight:normal;">US, 1969</text>
  <text x="392.201" y="208.11900000000003" svg_rhmargin="395.937" style="fill:#171615;font-family:FHEHBD+AdvOTbc475f09+20;font-size:7.47px;font-style:NORMAL;font-weight:normal;">–</text>
  <text x="395.943,400.067,404.192,408.316,412.441,415.331,420.695,424.82,428.944,433.069,435.474,437.492,440.84,443.717,445.734,448.663,454.805,458.541,460.947,462.964,467.088,471.213,474.949,476.966,479.955,485.32,489.055,493.18,496.445,499.71,502.587,505.521,507.927,512.051,514.928,517.334,519.351,521.757,525.882,528.288,531.553,533.57,536.586,542.339,547.704,553.069,557.193,560.929,562.946,565.894,569.63,573.754,576.631,580.367,583.632,585.65,587.667" y="208.11900000000003" svg_rhmargin="590.073" style="fill:#171615;font-family:FHEHAC+AdvOTbc475f09;font-size:7.47px;font-style:NORMAL;font-weight:normal;">2013 Counties, National Cancer Institute, DCCPS, Surveil-</text>
  <text x="361.587,363.605,367.341,371.465,374.73,377.995,381.429,386.793,390.059,392.935,396.2,399.936,402.813,406.078,410.203,413.628,417.752,420.629,424.753,428.489,431.366,435.102,441.243,443.26,446.677,450.413,454.537,457.414,461.15,464.415,466.432,468.45,470.467,474.203,478.327,481.593,484.858,488.286,492.022,495.758,498.634,501.04,504.305,510.447,513.324,516.744,521.257,524.134,527.87,531.994,535.26,539.384,541.4010000000001,544.862,547.738,551.003,553.021,556.286,560.022,562.899,566.164,570.289,573.716,579.081,583.206,586.082,588.1" y="217.07600000000002" svg_rhmargin="590.117" style="fill:#171615;font-family:FHEHAC+AdvOTbc475f09;font-size:7.47px;font-style:NORMAL;font-weight:normal;">lance Research Program, Surveillance Systems Branch, released April</text>
  <text x="361.587,365.712,369.836,373.961,378.085,380.102,382.619,386.744,390.48,393.357,396.622,400.747,403.255,407.379,411.504,414.026,416.432,420.556,423.82099999999997,426.327,432.469,436.594,440.33,443.595,449.737,453.934,457.199,460.076,462.551,466.676,470.8,474.925,479.05,481.542,484.419,488.543,492.668,498.81,500.827,503.704,506.58,508.696,512.82,516.945" y="226.03300000000002" svg_rhmargin="518.962" style="fill:#171615;font-family:FHEHAC+AdvOTbc475f09;font-size:7.47px;font-style:NORMAL;font-weight:normal;">2015, based on the November 2014 submission.</text>
  <text x="345.203,347.609,351.734,355.858,358.264,361.587,369.058,372.794,376.919,380.655,383.469,389.693,391.71,394.466,399.831,403.955,407.691,411.816,415.55199999999996,418.332,423.697,425.714,428.479,433.844,437.969,442.093,445.829,448.604,453.117,455.134,457.901,461.166,463.572,466.348,470.084,472.101,474.118,476.949,481.462,484.727,487.133,489.539,492.804,495.681,498.434,501.311,505.435,508.312,512.048,514.137,517.873,521.609,523.6260000000001,526.382,528.399,532.524,535.282,539.406,546.878,552.243,557.1450000000001,559.942,564.066,566.472,569.239,571.645,574.91,581.052,584.788,586.805" y="234.99" svg_rhmargin="590.07" style="fill:#171615;font-family:FHEHAC+AdvOTbc475f09;font-size:7.47px;font-style:NORMAL;font-weight:normal;">[16] Wang H, Zhang C, Kong L, et al. Better survival in PMRT of female</text>
  <text svg_rhmargin="445.161" x="361.587,365.712,368.588,371.854,375.59,378.466,380.872,382.392,385.657,389.393,393.517,396.783,400.048,402.925,404.387,408.512,412.248,414.654,416.671,419.936,424.061,426.466,429.343,430.861,436.614,438.631,441.037,445.162" y="243.947" style="fill:#171615;font-family:FHEHAC+AdvOTbc475f09;font-size:7.47px;font-style:NORMAL;font-weight:normal;">breast cancer patients with </text>
  <text x="446.626" y="243.947" svg_rhmargin="452.379" style="fill:#171615;font-family:FHEGPO+AdvP4C4E51;font-size:7.47px;font-style:NORMAL;font-weight:normal;">&gt;</text>
  <text x="452.409,456.534,457.965,462.09,465.355,469.091,472.827,475.233,477.25,480.986,484.251,485.743,487.76,491.496,497.638,501.762,505.887,507.397,511.522,515.646,519.771,523.036,525.912,527.9290000000001,529.392,533.128,534.607,538.733,542.857,546.981,551.106,553.123,556.859,559.265,561.283,565.407,569.531,571.937,576.062,579.798,582.674,585.94" y="243.947" svg_rhmargin="590.064" style="fill:#171615;font-family:FHEHAC+AdvOTbc475f09;font-size:7.47px;font-style:NORMAL;font-weight:normal;">5 negative lymph nodes: a population-based</text>
  <text x="361.587,364.464,366.87,370.994,375.119,378.855,380.872,383.413,390.884,394.149,398.274,400.291,403.556,405.574,409.698,412.96299999999997,415.498,417.904,422.417,426.153,428.17,430.576,432.593,438.735,442.86,445.736,449.001,451.407,453.989,458.113,462.238,466.362,470.487,472.504,476.628,480.753,482.77,486.035,490.16,494.284,498.489,502.613" y="252.90499999999997" svg_rhmargin="504.63" style="fill:#171615;font-family:FHEHAC+AdvOTbc475f09;font-size:7.47px;font-style:NORMAL;font-weight:normal;">study. Medicine (Baltimore) 2017;96:e5998.</text>
  <text x="345.203,347.609,351.734,355.858,358.264,361.587,366.1,368.117,372.242,376.042,380.945,382.962,386.701,391.603,395.727,399.852,403.58799999999997,407.393,412.759,414.776,418.505,424.73,427.995,431.771,436.285,438.302,442.09,445.355,447.761,451.501,455.237,457.254,459.271,463.066,468.43,470.448,472.465,476.589,478.607,481.872,485.996,490.121,493.857,496.263,500.387,504.512,506.529,510.653,514.389,516.407,519.672,523.408,525.4250000000001,529.277,532.542,536.666,540.402,543.279,547.015,550.28,552.686,555.951,558.828,560.845,563.722,566.128,568.145,571.41,574.2869999999999,578.142,581.878,586.002" y="261.919" svg_rhmargin="590.126" style="fill:#171615;font-family:FHEHAC+AdvOTbc475f09;font-size:7.47px;font-style:NORMAL;font-weight:normal;">[17] Liu T, Tong Z, He L, et al. Clinicopathological characteristics and</text>
  <text x="361.587,364.464,368.588,371.465,375.201,377.218,380.954,384.69,386.707,390.158,393.894,398.018,401.754,403.772,407.508,410.384,412.402,415.279,418.729,422.853,425.259,428.65,432.774,436.899,440.328,446.47,450.206,452.223,455.488,458.923,463.047,465.924,469.189,472.925,475.801,478.207,481.655,484.92,488.656,492.78,496.045,499.311,502.188,505.634,508.899,512.635,515.512,518.777,521.654,523.671,527.062,531.575,534.452,537.717,541.518,544.395,546.8009999999999,550.192,555.557,559.293,562.169,565.434,568.843,571.249,575.762,579.498,582.375,585.64,587.657" y="270.876" svg_rhmargin="590.063" style="fill:#171615;font-family:FHEHAC+AdvOTbc475f09;font-size:7.47px;font-style:NORMAL;font-weight:normal;">survival analysis of 87 male breast cancer cases. Breast Care (Basel)</text>
  <text x="361.587,365.712,369.836,373.961,378.085,380.102,384.227,386.244,390.442,394.566" y="279.83299999999997" svg_rhmargin="398.69" style="fill:#171615;font-family:FHEHAC+AdvOTbc475f09;font-size:7.47px;font-style:NORMAL;font-weight:normal;">2011;6:446</text>
  <text x="398.664" y="279.83299999999997" svg_rhmargin="402.4" style="fill:#171615;font-family:FHEHBD+AdvOTbc475f09+20;font-size:7.47px;font-style:NORMAL;font-weight:normal;">–</text>
  <text x="402.406,406.531,410.656" y="279.83299999999997" svg_rhmargin="412.673" style="fill:#171615;font-family:FHEHAC+AdvOTbc475f09;font-size:7.47px;font-style:NORMAL;font-weight:normal;">51.</text>
  <text x="345.203,347.609,351.734,355.858,358.264,361.587,366.1,370.224,374.348,377.225,381.35,385.085,387.491,391.688,395.813,398.69,401.552,409.024,411.041,413.911,418.424,421.689,423.774,427.899,431.635,434.511,438.247,442.372,446.108,449.001,454.366,456.383,459.262,462.998,467.123,471.247,474.983,479.107,483.232,486.968,489.874,495.24,497.257,500.136,503.401,505.807,508.696,512.432,514.45,516.4670000000001,519.354,526.826,530.562,532.579,535.8439999999999,538.742,542.867,545.743,549.008,552.744,555.621,558.0269999999999,560.907,564.172,567.908,572.033,575.363,578.628,581.505,583.522,586.418" y="288.79" svg_rhmargin="590.154" style="fill:#171615;font-family:FHEHAC+AdvOTbc475f09;font-size:7.47px;font-style:NORMAL;font-weight:normal;">[18] Bourhafour M, Belbaraka R, Souadka A, et al. Male breast cancer: a</text>
  <text x="361.587,364.464,367.729,371.854,375.978,378.855,381.261,386.134,390.258,392.664,397.528,401.653,405.777,409.902,414.762,418.027,421.763,424.64,427.905,430.782,435.68,439.416,441.822,446.678,450.414,455.238,462.711,466.835,469.712,473.836,477.101,480.366,484.102,488.227,493.107,495.124,499.248,502.125,504.531,506.548,508.954,513.079,515.485,517.502,521.627,525.751,527.768,532.675,537.188,544.66,550.025,554.898,560.262,563.528,566.405,571.281,577.423,581.547,583.953,587.219" y="297.747" svg_rhmargin="590.096" style="fill:#171615;font-family:FHEHAC+AdvOTbc475f09;font-size:7.47px;font-style:NORMAL;font-weight:normal;">report of 127 cases at a Moroccan institution. BMC Res Notes</text>
  <text x="361.587,365.712,369.836,373.961,378.085,380.102,384.227,386.244,390.442,394.566,398.691" y="306.705" svg_rhmargin="400.708" style="fill:#171615;font-family:FHEHAC+AdvOTbc475f09;font-size:7.47px;font-style:NORMAL;font-weight:normal;">2011;4:219.</text>
  <text x="345.203,347.609,351.734,355.858,358.264,361.587,365.323,371.464,373.482,375.888,380.013,384.262,389.627,394.992,397.009,401.156,404.892,408.628,411.504,413.522,417.646,423.399,427.63,433.384,435.401,439.592,443.328,447.064,452.817,456.553,459.818,462.695,466.916,472.281,477.645,479.662,483.866,487.131,489.537,493.73,497.466,499.483,501.5,505.691,511.056,517.198,520.463,523.34,525.357,528.622,532.358,536.483,540.669,546.033,549.769,553.894,557.159,560.509,563.386,567.539,571.275,575.399,578.664,580.682,583.947,586.353" y="315.662" svg_rhmargin="590.089" style="fill:#171615;font-family:FHEHAC+AdvOTbc475f09;font-size:7.47px;font-style:NORMAL;font-weight:normal;">[19] Smith RA, Saslow D, Sawyer KA, et al. American Cancer Society</text>
  <text x="361.587,365.323,369.448,371.465,375.59,378.855,380.872,382.889,387.097,390.362,393.23900000000003,395.827,398.233,402.357,405.23400000000004,407.788,411.913,414.79,418.055,421.791,424.738,427.144,429.727,432.992,436.728,440.853,444.118,447.383,450.26,452.856,455.733,458.998,461.875,465.14,468.405,472.529,474.547,478.671,482.407,484.424,487.039,491.163,495.288,499.412,503.148,505.554,508.81899999999996,511.415,515.539,519.664,523.788,527.913,529.9300000000001,532.56,537.925,543.29,545.883,551.248,554.984,559.109,562.374,565.639,568.516,571.11,573.987,576.552,581.918,583.935,585.953" y="324.676" svg_rhmargin="590.077" style="fill:#171615;font-family:FHEHAC+AdvOTbc475f09;font-size:7.47px;font-style:NORMAL;font-weight:normal;">guidelines for breast cancer screening: update 2003. CA Cancer J Clin</text>
  <text x="361.587,365.712,369.836,373.961,378.085,380.102,384.227,388.351,390.441,394.566,398.69" y="333.633" svg_rhmargin="402.814" style="fill:#171615;font-family:FHEHAC+AdvOTbc475f09;font-size:7.47px;font-style:NORMAL;font-weight:normal;">2003;53:141</text>
  <text x="402.803" y="333.633" svg_rhmargin="406.539" style="fill:#171615;font-family:FHEHBD+AdvOTbc475f09+20;font-size:7.47px;font-style:NORMAL;font-weight:normal;">–</text>
  <text x="406.544,410.67,414.795" y="333.633" svg_rhmargin="416.812" style="fill:#171615;font-family:FHEHAC+AdvOTbc475f09;font-size:7.47px;font-style:NORMAL;font-weight:normal;">69.</text>
  <text x="345.203,347.609,351.734,355.858,358.264,361.587,366.951,371.076,375.2,378.465,381.342,384.219,388.343,392.468,393.956,401.428,405.552,407.569,409.035,411.911,415.647,418.053,422.178,424.195,425.645,428.05,430.067,431.541,436.442,439.319,442.584,444.012,446.889,448.906,450.362,453.627,456.033,457.448,461.184,463.202,465.219,466.689,474.16,477.896,479.914,483.179,484.659,488.783,491.66,494.925,498.661,501.538,503.944,505.407,508.672,512.408,516.532,519.797,523.063,525.939,527.956,529.386,533.122,534.601,538.727,542.851,546.975,551.1,553.117,556.853,559.259,561.277,565.401,569.525,571.931,576.056,579.792,582.668,585.934" y="342.59" svg_rhmargin="590.058" style="fill:#171615;font-family:FHEHAC+AdvOTbc475f09;font-size:7.47px;font-style:NORMAL;font-weight:normal;">[20] Anderson WF, Jatoi I, Tse J, et al. Male breast cancer: a population-based</text>
  <text x="361.587,364.853,368.977,375.119,379.243,382.979,385.856,387.873,390.838,394.962,399.087,401.553,407.306,409.323,411.729,415.854,418.389,420.795,424.061,430.202,433.938,435.956,439.221,441.745,445.869,448.746,452.011,455.747,458.624,461.03000000000003,463.57,466.835,470.571,474.695,477.961,481.226,484.102,486.11899999999997,488.626,491.503,494.012,499.377,501.394,503.412,507.537,510.056,516.198,520.322,523.587,527.712,529.729,532.278,536.402,540.527,544.651,548.775,550.793,554.917,559.042,561.059,565.184,569.308" y="351.547" svg_rhmargin="573.432" style="fill:#171615;font-family:FHEHAC+AdvOTbc475f09;font-size:7.47px;font-style:NORMAL;font-weight:normal;">comparison with female breast cancer. J Clin Oncol 2010;28:232</text>
  <text x="573.504" y="351.547" svg_rhmargin="577.24" style="fill:#171615;font-family:FHEHBD+AdvOTbc475f09+20;font-size:7.47px;font-style:NORMAL;font-weight:normal;">–</text>
  <text x="577.246,581.37" y="351.547" svg_rhmargin="583.387" style="fill:#171615;font-family:FHEHAC+AdvOTbc475f09;font-size:7.47px;font-style:NORMAL;font-weight:normal;">9.</text>
  <text x="345.203,347.609,351.734,355.858,358.264,361.587,369.058,372.794,376.919,380.655,383.128,388.493,392.617,396.741,399.618,401.635,405.371,409.496,412.761,416.026,418.218,421.094,423.111,425.361,430.725,433.602,437.726,440.603,443.48,445.656,451.021,453.038,455.237,460.991,464.727,466.744,468.761,472.497,476.233,480.358,483.623,486.5,488.74,492.476,494.493,496.734,499.999,502.40500000000003,504.556,508.292,510.31,512.327,514.534,522.005,525.741,527.759,531.024,533.241,537.365,540.242,543.507,547.243,550.12,552.526,554.782,558.047,561.783,564.66,567.925,569.942,574.067,578.191,584.333,588.069" y="360.505" svg_rhmargin="590.086" style="fill:#171615;font-family:FHEHAC+AdvOTbc475f09;font-size:7.47px;font-style:NORMAL;font-weight:normal;">[21] Wang-Rodriguez J, Cross K, Gallagher S, et al. Male breast carcinoma:</text>
  <text x="361.587,364.853,368.977,371.854,374.73,377.995,380.013,383.749,386.247,388.264,392.388,396.513,399.286,403.41,405.81600000000003,408.583,413.096,418.46,420.477,423.266,427.39,432.755,434.772,437.551,442.916,444.933,447.339,451.463,455.588,457.605,460.397,466.621,469.886,472.762,476.887,479.293,485.435,488.7,492.824,494.841,497.697,501.433,505.558,509.683,512.437,516.561,520.686,524.811,527.573,533.327,535.344,537.75,541.875,544.693,547.099,549.976,553.241,556.977,559.383,565.525,568.79,572.915,575.3209999999999,578.14,581.876,586.0" y="369.462" svg_rhmargin="590.124" style="fill:#171615;font-family:FHEHAC+AdvOTbc475f09;font-size:7.47px;font-style:NORMAL;font-weight:normal;">correlation of ER, PR, Ki-67, Her2-Neu, and p53 with treatment and</text>
  <text x="361.587,364.464,368.588,371.465,375.201,377.218,380.954,384.69,386.708,388.725,391.292,395.02799999999996,397.528,400.405,402.811,406.935,411.06,414.796,417.313,421.437,423.843,426.327,430.451,434.576,437.098,440.363,444.099,446.976,450.241,453.118,455.135,457.619,465.091,469.216,473.341,475.873,479.997,483.733,486.139,490.264,494.388,496.405,498.945,503.07,507.194,511.318,515.443,517.46,521.585,525.709,527.727,531.851,535.975" y="378.476" svg_rhmargin="540.099" style="fill:#171615;font-family:FHEHAC+AdvOTbc475f09;font-size:7.47px;font-style:NORMAL;font-weight:normal;">survival, a study of 65 cases. Mod Pathol 2002;15:853</text>
  <text x="540.169" y="378.476" svg_rhmargin="543.905" style="fill:#171615;font-family:FHEHBD+AdvOTbc475f09+20;font-size:7.47px;font-style:NORMAL;font-weight:normal;">–</text>
  <text x="543.911,548.036,552.161" y="378.476" svg_rhmargin="554.178" style="fill:#171615;font-family:FHEHAC+AdvOTbc475f09;font-size:7.47px;font-style:NORMAL;font-weight:normal;">86.</text>
  <text x="345.203,347.609,351.734,355.858,358.264,361.587,366.951,369.828,372.705,374.722,378.458,382.583,384.716,390.08,395.445,397.462,399.568,405.71,409.834,412.711,416.835,420.101" y="387.433" svg_rhmargin="424.225" style="fill:#171615;font-family:FHEHAC+AdvOTbc475f09;font-size:7.47px;font-style:NORMAL;font-weight:normal;">[22] Arslan UY, Oksüzo</text>
  <text x="424.289" y="387.319" svg_rhmargin="428.025" style="fill:#171615;font-family:FHIDOO+AdvP4C4E59;font-size:7.47px;font-style:NORMAL;font-weight:normal;">?</text>
  <text x="424.289,428.025,430.043,434.168,436.251,440.764,442.781,444.867,451.009,454.274,458.399,461.664,467.883,469.9,472.777,474.855,480.997,483.014,485.116,488.382,490.788,492.883,496.618,498.636,500.653,502.747,508.889,513.013,515.419,518.684,522.809,528.951,532.216,534.379,538.503,540.909,542.996,547.121,551.245,555.369,557.775,563.917,567.182,569.588,573.324,576.201,578.709,582.445,584.851,586.868" y="387.433" svg_rhmargin="590.133" style="fill:#171615;font-family:FHEHAC+AdvOTbc475f09;font-size:7.47px;font-style:NORMAL;font-weight:normal;">glu B, Ozdemir N, et al. Outcome of non-metastatic</text>
  <text x="361.587,367.729,371.465,373.482,376.747,379.275,383.399,386.276,389.541,393.277,396.153,398.559,401.1,404.365,408.101,412.225,415.49,418.755,421.632,423.649,426.156,430.28,434.404,438.529,441.065,445.189,448.925,451.331,453.348,456.614,460.738,463.144,466.021,468.038,470.599,478.071,481.336,485.461,487.947,494.088,498.213,501.478,505.602,507.61899999999997,510.168,514.293,518.417,522.542,526.666,528.684,532.808,536.932,538.95,543.074,547.199" y="396.403" svg_rhmargin="551.323" style="fill:#171615;font-family:FHEHAC+AdvOTbc475f09;font-size:7.47px;font-style:NORMAL;font-weight:normal;">male breast cancer: 118 patients. Med Oncol 2012;29:554</text>
  <text x="551.394" y="396.403" svg_rhmargin="555.13" style="fill:#171615;font-family:FHEHBD+AdvOTbc475f09+20;font-size:7.47px;font-style:NORMAL;font-weight:normal;">–</text>
  <text x="555.136,559.261,563.386" y="396.403" svg_rhmargin="565.403" style="fill:#171615;font-family:FHEHAC+AdvOTbc475f09;font-size:7.47px;font-style:NORMAL;font-weight:normal;">60.</text>
  <text x="345.203,347.609,351.733,355.858,358.264,361.587,365.322,369.447,371.464,375.589,377.006,379.883,385.247,387.264,388.684,394.049,397.785,401.05,405.175,409.299,411.316,414.58099999999996,416.008,420.521,425.886,427.903,429.329,435.553,437.571,440.448,443.324,446.589,450.714,452.118,457.483,461.996,464.013,465.441,470.342,474.467,477.73199999999997,479.103,481.12,487.262,491.461,495.197,498.462,500.868,502.232,506.357,508.76300000000003,510.169,513.046,516.782,520.047,523.312,524.738,526.756,530.881,532.278,538.42,542.156,544.173,547.438,548.831,552.956,555.832,559.098,562.833,565.781,568.1869999999999,569.58,572.845,576.581,580.705,583.971,587.236" y="405.36" svg_rhmargin="590.113" style="fill:#171615;font-family:FHEHAC+AdvOTbc475f09;font-size:7.47px;font-style:NORMAL;font-weight:normal;">[23] Shin JY, Kachnic LA, Hirsch AE. The impact of race in male breast cancer</text>
  <text x="361.587,363.993,366.87,370.135,373.871,376.277,382.505,385.77,389.895,392.301,394.07,397.806,401.93,406.055,407.846,411.97,416.095,418.501,421.766,425.89,432.108,435.373,437.154,439.171,443.296,445.09,447.496,451.621,454.88599999999997,456.712,462.077,466.201,468.219,470.625,473.89,478.015,479.841,483.577,485.983,489.719,492.125,495.39,498.266,500.283,502.12,505.856,507.619,511.744,515.868,519.993,524.117,526.135,529.871,532.277,534.376,538.501,542.625,545.031,549.156,552.891,555.768,559.033,563.158,564.988,568.724,572.849,576.585,578.602,582.338,585.214,587.232" y="414.318" svg_rhmargin="590.109" style="fill:#171615;font-family:FHEHAC+AdvOTbc475f09;font-size:7.47px;font-style:NORMAL;font-weight:normal;">treatment and outcome in the United States: a population-based analysis</text>
  <text x="361.587,365.712,368.118,370.658,374.782,376.8,380.924,385.049,389.174,391.69,395.814,399.55,401.956,403.973,407.238,411.363,413.769,416.645,418.662,421.167,423.573,427.698,430.104,432.619,435.49600000000004,438.004,442.517,445.394,448.659,452.395,455.272,457.678,460.226,465.591,469.327,473.451,476.716,479.982,482.85900000000004,485.396,489.52,493.644,497.769,501.893,503.911,508.035,512.16,516.284,520.408,522.426,526.55,530.675,534.799,538.924,543.048,547.173" y="423.275" svg_rhmargin="549.19" style="fill:#171615;font-family:FHEHAC+AdvOTbc475f09;font-size:7.47px;font-style:NORMAL;font-weight:normal;">of 4,279 patients. Int J Breast Cancer 2014;2014:685842.</text>
  <text x="345.203,347.609,351.733,355.858,358.264,361.587,367.34,370.605,374.729,378.465,380.48199999999997,383.241,388.606,390.623,393.332,398.697,402.821,406.946,410.681,413.558,416.291,421.655,423.67199999999997,426.438,429.315,433.439,437.563,441.688,445.424,448.15,451.885,453.902,456.596,461.962,465.698,468.963,470.98,474.716,476.733,479.499,483.623,485.641,488.517,492.642,496.378,499.254,501.272,503.678,505.695,508.96,511.837,514.589,516.606,520.731,523.432,526.698,528.715,530.732,534.94,536.958,540.223,543.959,545.976,548.659,552.784,555.661,558.926,561.802,565.068,569.192,571.675,575.411,577.817,579.834,583.959,588.083" y="432.232" svg_rhmargin="590.1" style="fill:#171615;font-family:FHEHAC+AdvOTbc475f09;font-size:7.47px;font-style:NORMAL;font-weight:normal;">[24] Dehal A, Abbas A, Johna S. Racial disparities in clinical presentation,</text>
  <text x="361.587,364.464,368.588,371.465,375.201,377.218,380.483,384.219,386.236,390.442,392.848,395.724,398.99,402.726,405.131,411.273,414.538,418.663,421.069,425.248,428.984,433.109,437.234,441.405,443.422,447.547,449.952,454.077,458.201,461.078,465.202,467.22,469.626,473.362,475.379,479.556,483.68,487.805,490.21,493.476,497.6,503.819,507.084,509.961,514.08,518.204,520.6099999999999,524.738,530.491,534.615,540.757,544.022,548.147,552.345,558.099,560.117,562.523,566.648,570.827,574.951,577.828,581.093,584.829,587.706" y="441.246" svg_rhmargin="590.112" style="fill:#171615;font-family:FHEHAC+AdvOTbc475f09;font-size:7.47px;font-style:NORMAL;font-weight:normal;">surgical treatment and in-hospital outcomes of women with breast</text>
  <text x="361.587,364.852,368.588,372.713,375.978,379.243,382.12,384.137,386.134,389.87,393.994,397.73,399.747,403.483,406.36,408.377,411.254,413.231,417.355,419.761,421.734,425.859,429.595,432.001,434.018,438.143,442.267,448.02,450.038,454.162,457.42699999999996,459.432,461.449,465.574,469.698,473.434,475.84,477.857,481.123,485.247,487.653,489.646,492.523,496.259,502.401,506.525,508.543,511.808,513.796,517.921,521.657,524.063,527.799,531.923,535.659,538.536,541.801,543.8180000000001,545.825,550.338,553.215,556.48,560.216,563.093,565.4989999999999,567.48,572.845,576.581,580.705,583.97,587.236" y="450.203" svg_rhmargin="590.113" style="fill:#171615;font-family:FHEHAC+AdvOTbc475f09;font-size:7.47px;font-style:NORMAL;font-weight:normal;">cancer: analysis of nationwide inpatient sample database. Breast Cancer</text>
  <text x="361.587,366.952,370.217,373.094,375.646,380.548,383.425,386.69,390.426,392.832,395.318,399.442,403.567,407.691,411.816,413.833,417.957,422.082,426.206,428.31,432.435,436.559" y="459.16" svg_rhmargin="440.683" style="fill:#171615;font-family:FHEHAC+AdvOTbc475f09;font-size:7.47px;font-style:NORMAL;font-weight:normal;">Res Treat 2013;139:561</text>
  <text x="440.673" y="459.16" svg_rhmargin="444.409" style="fill:#171615;font-family:FHEHBD+AdvOTbc475f09+20;font-size:7.47px;font-style:NORMAL;font-weight:normal;">–</text>
  <text x="444.415,448.54" y="459.16" svg_rhmargin="450.557" style="fill:#171615;font-family:FHEHAC+AdvOTbc475f09;font-size:7.47px;font-style:NORMAL;font-weight:normal;">9.</text>
  <text x="345.203,347.609,351.733,355.858,358.264,361.587,365.322,369.447,373.572,376.099,380.612,382.629,385.17,390.534,394.659,398.395,402.519,406.255,408.809,413.322,419.464,421.481,424.001,429.366,433.491,437.226,441.351,445.087,447.641,450.517,452.534,455.067,458.332,460.738,463.231,466.966,468.984,471.001,473.548,478.45,482.574,485.839,488.401,492.525,495.402,499.526,503.262,507.387,511.511,514.388,516.794,518.811,522.076,524.625,528.361,532.097,534.114,538.239,541.504,544.07,548.194,550.5999999999999,553.084,556.349,558.366,560.384,564.508,566.525,569.791,573.526,575.543,578.14,581.875,586.0" y="468.117" svg_rhmargin="590.124" style="fill:#171615;font-family:FHEHAC+AdvOTbc475f09;font-size:7.47px;font-style:NORMAL;font-weight:normal;">[25] Sun B, Zhang LN, Zhang J, et al. The prognostic value of clinical and</text>
  <text x="361.587,365.712,369.448,371.854,375.978,380.102,382.12,386.244,389.98,392.085,395.34999999999997,396.791,399.197,402.462,406.198,408.604,412.728,415.605,418.87,421.747,423.264,425.281,429.406,430.917,435.042,439.166,443.291,449.432,452.698,455.103,458.839,461.716,464.122,467.858,470.264,472.281,475.546,477.061,481.185,485.31,488.575,491.516,495.252,499.377,501.394,504.659,506.142,512.285,516.021,518.038,521.303,522.753,526.878,529.754,533.019,536.755,539.703,542.1089999999999,543.558,546.824,550.559,554.684,557.949,561.214,564.091,566.1080000000001,567.651,573.016,575.893,577.91,581.646,585.771,587.266" y="477.075" svg_rhmargin="590.143" style="fill:#171615;font-family:FHEHAC+AdvOTbc475f09;font-size:7.47px;font-style:NORMAL;font-weight:normal;">pathologic features in nonmetastatic operable male breast cancer. Asian J</text>
  <text x="361.587,366.952,371.076,375.201,378.078,382.202,384.219,386.757,390.881,395.006,399.13,403.254,405.272,409.396,413.521,415.611,419.735" y="486.032" svg_rhmargin="423.859" style="fill:#171615;font-family:FHEHAC+AdvOTbc475f09;font-size:7.47px;font-style:NORMAL;font-weight:normal;">Androl 2016;18:90</text>
  <text x="423.836" y="486.032" svg_rhmargin="427.572" style="fill:#171615;font-family:FHEHBD+AdvOTbc475f09+20;font-size:7.47px;font-style:NORMAL;font-weight:normal;">–</text>
  <text x="427.577,431.702" y="486.032" svg_rhmargin="433.719" style="fill:#171615;font-family:FHEHAC+AdvOTbc475f09;font-size:7.47px;font-style:NORMAL;font-weight:normal;">5.</text>
  <text x="345.203,347.609,351.733,355.858,358.264,361.587,366.099,368.117,372.242,374.228,379.982,381.999,383.923,389.677,391.694,394.959,396.905,402.658,404.675,406.656,412.02,416.145,419.41,423.535,425.476,432.948,434.965,436.871,442.236,444.253,446.27,450.476,452.494,455.759,459.883,464.008,467.744,470.15,474.274,478.398,480.416,484.54,488.276,490.293,493.558,495.543,498.808,502.933,506.669,509.545,513.281,516.546,518.952,522.217,525.094,527.112,529.988,532.394,534.411,537.677,540.554,542.594,546.33,550.454,554.579,556.482,559.359,563.484,566.36,570.096,572.114,575.849,579.585,581.6020000000001,583.579,587.703" y="495.046" svg_rhmargin="590.109" style="fill:#171615;font-family:FHEHAC+AdvOTbc475f09;font-size:7.47px;font-style:NORMAL;font-weight:normal;">[26] Liu D, Xie G, Chen M. Clinicopathologic characteristics and survival of</text>
  <text x="361.587,367.729,371.465,373.482,376.747,379.275,383.399,386.276,389.541,393.277,396.153,398.559,401.1,404.365,408.101,412.225,415.49,418.755,421.632,423.649,426.156,428.561,432.686,435.092,437.607,440.48400000000004,442.992,448.358,450.375,452.393,456.518,459.037,465.178,469.303,472.568,476.693,478.71,481.259,485.383,489.507,493.632,497.756,499.774,503.898,508.022,510.04,514.164,518.289" y="504.003" svg_rhmargin="522.413" style="fill:#171615;font-family:FHEHAC+AdvOTbc475f09;font-size:7.47px;font-style:NORMAL;font-weight:normal;">male breast cancer. Int J Clin Oncol 2014;19:280</text>
  <text x="522.481" y="504.003" svg_rhmargin="526.217" style="fill:#171615;font-family:FHEHBD+AdvOTbc475f09+20;font-size:7.47px;font-style:NORMAL;font-weight:normal;">–</text>
  <text x="526.222,530.348" y="504.003" svg_rhmargin="532.365" style="fill:#171615;font-family:FHEHAC+AdvOTbc475f09;font-size:7.47px;font-style:NORMAL;font-weight:normal;">7.</text>
  <text x="345.203,347.609,351.733,355.858,358.264,361.587,365.711,367.728,370.993,373.011,377.135,380.012,381.484,385.997,391.362,393.379,394.862,400.615,403.881,411.352,413.37,415.776,418.182,419.692,423.816,425.83299999999997,427.232,431.356,433.373,436.25,440.374,443.64,446.517,448.036,453.401,460.873,462.89,464.306,467.571,469.97700000000003,471.449,475.185,477.202,479.219,480.689,488.161,491.897,496.021,499.757,503.493,506.758,512.9,516.165,520.29,522.6959999999999,524.168,528.294,530.6999999999999,532.163,538.304,542.04,544.058,547.323,548.829,552.954,555.83,559.095,562.831,565.708,568.1139999999999,569.577,572.842,576.578,580.702,583.968,587.233" y="512.96" svg_rhmargin="590.11" style="fill:#171615;font-family:FHEHAC+AdvOTbc475f09;font-size:7.47px;font-style:NORMAL;font-weight:normal;">[27] Fields EC, DeWitt P, Fisher CM, et al. Management of male breast cancer</text>
  <text x="361.587,363.605,367.73,372.302,374.708,378.832,382.097,386.645,392.01,396.135,398.152,400.558,403.823,407.948,412.496,416.231,418.637,422.373,424.779,428.044,430.921,432.938,437.552,441.288,445.773,448.649,452.774,455.65,459.386,462.723,464.74,466.757,468.775,472.511,476.635,479.9,483.165,485.182,489.763,493.028,497.153,499.17,503.294,506.56,512.701,514.719,518.843,520.861,524.985,528.721,532.457,537.041,540.777,544.901,549.026,553.595,556.86,560.984,565.109,569.638,572.515,575.78,578.657,582.781,584.798,587.204" y="521.9169999999999" svg_rhmargin="590.081" style="fill:#171615;font-family:FHEHAC+AdvOTbc475f09;font-size:7.47px;font-style:NORMAL;font-weight:normal;">in the United States: a surveillance, epidemiology and end results</text>
  <text x="361.587,365.323,369.448,373.184,375.201,378.937,381.881,383.899,386.775,388.792,391.292,393.698,397.823,400.229,402.743,405.62,408.129,413.494,417.23,421.354,423.372,427.108,429.514,431.995,438.137,442.261,445.6,449.725,451.742,454.217,458.73,460.748,464.872,466.889,469.41,473.534,477.659,481.395,484.272,486.756,490.881,495.006,499.13,503.255,505.272,509.397,513.521,515.611,519.735,523.86" y="530.875" svg_rhmargin="527.984" style="fill:#171615;font-family:FHEHAC+AdvOTbc475f09;font-size:7.47px;font-style:NORMAL;font-weight:normal;">analysis. Int J Radiat Oncol Biol Phys 2013;87:747</text>
  <text x="527.98" y="530.875" svg_rhmargin="531.716" style="fill:#171615;font-family:FHEHBD+AdvOTbc475f09+20;font-size:7.47px;font-style:NORMAL;font-weight:normal;">–</text>
  <text x="531.722,535.847,539.972" y="530.875" svg_rhmargin="541.989" style="fill:#171615;font-family:FHEHAC+AdvOTbc475f09;font-size:7.47px;font-style:NORMAL;font-weight:normal;">52.</text>
  <text x="345.203,347.609,351.733,355.858,358.264,361.587,367.728,371.464,375.589,377.606,380.871,384.996,388.627,393.992,399.356,401.373,405.01,408.746,411.623,413.64,417.765,421.501,425.625,428.031,430.048,433.784,437.909,441.518,446.882,448.899,452.515,456.251,459.987,462.393,466.12899999999996,469.692,477.164,479.181,482.787,486.052,488.458,492.084,495.82,497.838,499.855,503.422,510.894,514.63,516.647,519.912,523.547,527.671,530.548,533.813,537.549,540.426,542.832,546.449,549.715,553.451,557.575,560.84,564.105,566.982,570.599,572.617,576.742,580.293,582.699,586.823" y="539.832" svg_rhmargin="590.088" style="fill:#171615;font-family:FHEHAC+AdvOTbc475f09;font-size:7.47px;font-style:NORMAL;font-weight:normal;">[28] Nahleh ZA, Srikantiah R, Safa M, et al. Male breast cancer in the</text>
  <text x="361.587,365.323,368.588,370.994,374.259,377.136,380.872,384.996,387.873,390.668,394.404,396.81,399.216,402.952,404.969,407.846,410.723,413.457,417.582,421.706,425.831,429.955,431.972,435.708,438.114,440.214,444.338,448.463,450.48,453.195,456.931,459.658,462.923,467.048,473.19,477.314,481.05,483.927,487.663,490.068,492.086,495.822,499.087,501.891,505.627,509.751,513.487,515.505,519.241,522.117,524.135,527.011,529.028,531.766,537.13,540.866,544.991,548.256,551.521,554.3979999999999,557.162,561.287,565.411,569.536,573.66,575.678,579.802,583.926,588.051" y="548.846" svg_rhmargin="590.068" style="fill:#171615;font-family:FHEHAC+AdvOTbc475f09;font-size:7.47px;font-style:NORMAL;font-weight:normal;">veterans affairs population: a comparative analysis. Cancer 2007;109:</text>
  <text x="361.587,365.712,369.838,373.963" y="557.803" svg_rhmargin="378.087" style="fill:#171615;font-family:FHEHAC+AdvOTbc475f09;font-size:7.47px;font-style:NORMAL;font-weight:normal;">1471</text>
  <text x="378.142" y="557.803" svg_rhmargin="381.878" style="fill:#171615;font-family:FHEHBD+AdvOTbc475f09+20;font-size:7.47px;font-style:NORMAL;font-weight:normal;">–</text>
  <text x="381.884,386.008" y="557.803" svg_rhmargin="388.025" style="fill:#171615;font-family:FHEHAC+AdvOTbc475f09;font-size:7.47px;font-style:NORMAL;font-weight:normal;">7.</text>
  <text x="345.204,347.61,351.734,355.859,358.265,361.587,366.1,368.117,370.771,376.995,380.731,382.748,384.766,388.501,394.643,397.358,404.83,406.847,409.489,414.854,418.978,422.714,424.731,427.996,430.69,436.443,438.46,441.121,445.634,448.899,453.023,455.041,459.165,462.43,465.307,467.991,473.356,475.373,478.026,481.291,483.697,486.359,490.095,492.112,494.129,496.789,502.154,505.89,510.015,513.28,516.545,519.4219999999999,522.129,526.254,528.66,531.313,533.719,537.843,541.108,543.785,547.909,550.786,554.051,557.787,560.664,563.0699999999999,565.724,567.741,571.866,574.567,580.709,583.974,588.099" y="566.76" svg_rhmargin="590.116" style="fill:#171615;font-family:FHEHAC+AdvOTbc475f09;font-size:7.47px;font-style:NORMAL;font-weight:normal;">[29] El Hajjam M, Khaiz D, Benider A, et al. Cancer of the breast in men.</text>
  <text x="361.588,366.953,371.077,373.954,378.078,382.203,386.327,389.204,391.746,395.871,398.277,400.76,404.885,409.01,411.532,414.797,418.533,421.409,424.675,427.551,429.568,432.11,434.987,437.495,442.861,446.985,449.003,451.88,454.389,456.795,460.919,464.655,467.532,469.549,472.426,474.832,477.348,481.472,485.597,489.721,493.845,495.863,499.987,504.112,508.236,510.253,514.378,518.502" y="575.717" svg_rhmargin="522.626" style="fill:#171615;font-family:FHEHAC+AdvOTbc475f09;font-size:7.47px;font-style:NORMAL;font-weight:normal;">Apropos of 50 cases. J Chir (Paris) 1995;132:131</text>
  <text x="522.708" y="575.717" svg_rhmargin="526.444" style="fill:#171615;font-family:FHEHBD+AdvOTbc475f09+20;font-size:7.47px;font-style:NORMAL;font-weight:normal;">–</text>
  <text x="526.45,530.575" y="575.717" svg_rhmargin="532.592" style="fill:#171615;font-family:FHEHAC+AdvOTbc475f09;font-size:7.47px;font-style:NORMAL;font-weight:normal;">6.</text>
  <text x="345.204,347.61,351.734,355.859,358.265,361.587,365.712,369.448,372.324,376.449,378.481,382.217,384.234,386.191,391.556,393.573,399.715,401.781,404.658,410.882,412.899,414.876,420.241,424.365,428.49,430.522,433.399,435.416,437.382,440.647,443.053,445.092,448.828,450.845,452.862,454.843,460.208,462.225,464.242,468.367,470.384,473.649,477.858,481.983,485.718,488.124,492.249,496.373,498.391,502.515,506.251,508.268,511.534,515.269,517.2860000000001,519.297,522.562,526.686,530.422,533.299,537.035,540.3,542.706,546.053,548.93,550.947,553.824,556.23,558.247,561.513,564.39,566.404,570.529,572.935,574.965,581.107,584.843,586.86" y="584.674" svg_rhmargin="590.125" style="fill:#171615;font-family:FHEHAC+AdvOTbc475f09;font-size:7.47px;font-style:NORMAL;font-weight:normal;">[30] Park S, Kim JH, Koo J, et al. Clinicopathological characteristics of male</text>
  <text x="361.588,365.712,368.589,371.854,375.59,378.467,380.873,383.413,386.678,390.414,394.539,397.804,401.069,403.946,405.963,408.469,413.834,417.958,422.083,424.959,428.31,430.327,432.788,440.26,443.525,447.65,450.191,453.068,455.52,459.645,463.769,467.894,472.018,474.035,478.16,482.284,484.374,488.499,492.623" y="593.6320000000001" svg_rhmargin="496.747" style="fill:#171615;font-family:FHEHAC+AdvOTbc475f09;font-size:7.47px;font-style:NORMAL;font-weight:normal;">breast cancer. Yonsei Med J 2008;49:978</text>
  <text x="496.743" y="593.6320000000001" svg_rhmargin="500.479" style="fill:#171615;font-family:FHEHBD+AdvOTbc475f09+20;font-size:7.47px;font-style:NORMAL;font-weight:normal;">–</text>
  <text x="500.485,504.61,508.735" y="593.6320000000001" svg_rhmargin="510.752" style="fill:#171615;font-family:FHEHAC+AdvOTbc475f09;font-size:7.47px;font-style:NORMAL;font-weight:normal;">86.</text>
  <text x="345.204,347.61,351.734,355.859,358.265,361.587,366.952,370.688,373.953,378.077,380.095,384.22,385.906,389.642,391.659,393.333,398.697,402.433,405.698,409.823,413.947,418.072,421.808,423.491,429.716,431.733,433.356,439.581,443.317,446.193,449.07,452.806,456.996,460.26099999999997,461.871,468.014,470.031,471.68,479.152,482.888,484.905,488.16999999999996,489.877,494.002,496.878,500.143,503.879,506.756,509.162,510.795,514.06,517.796,521.921,525.251,528.516,531.393,533.4100000000001,535.058,539.183,543.308,544.923,548.188,551.924,554.801,558.066,559.775,562.652,565.917,570.042,574.166,577.043,579.449,582.3259999999999,583.981,587.717" y="602.5889999999999" svg_rhmargin="590.123" style="fill:#171615;font-family:FHEHAC+AdvOTbc475f09;font-size:7.47px;font-style:NORMAL;font-weight:normal;">[31] Rachid S, Yacouba H, Hassane N. Male breast cancer: 22 case reports at</text>
  <text x="361.588,363.994,368.118,371.383,374.173,380.315,384.051,386.457,388.475,392.599,396.723,400.459,402.476,405.295,411.519,415.643,418.52,422.645,424.662,427.068,430.804,432.82099999999997,435.623,439.747,442.153,444.92,451.062,453.079,456.815,462.957,466.222,469.958,472.364,478.506,480.633,484.369,487.634,490.511,493.275,495.681,503.152,506.418,509.294,511.7,514.476,519.841,522.247,525.123,527.141,530.406,534.142,536.641,538.658,541.404,545.528,549.264,553.389,556.143,561.508,563.914,566.7909999999999,569.578,577.051,580.316,584.441,587.266" y="611.6030000000001" svg_rhmargin="590.143" style="fill:#171615;font-family:FHEHAC+AdvOTbc475f09;font-size:7.47px;font-style:NORMAL;font-weight:normal;">the National Hospital of Niamey-Niger (West Africa). Pan Afr Med J</text>
  <text x="361.588,365.712,369.837,373.961,378.086,380.103,384.228,386.245,390.443,394.567" y="620.56" svg_rhmargin="396.584" style="fill:#171615;font-family:FHEHAC+AdvOTbc475f09;font-size:7.47px;font-style:NORMAL;font-weight:normal;">2009;3:15.</text>
  <text x="345.204,347.61,351.734,355.859,358.265,361.587,365.712,368.977,373.101,375.507,377.525,383.752,387.488,391.613,393.787,396.193,399.929,401.94599999999997,404.161,409.062,413.187,416.452,418.616,422.742,424.759,428.883,430.975,435.1,438.836,442.572,444.751,448.876,451.282,453.482,459.625,463.36,465.378,468.643,470.829,474.954,477.83,481.096,484.831,487.779,490.185,492.371,495.636,499.372,503.497,506.762,510.027,512.904,514.921,517.144,521.657,524.534,527.799,531.535,534.411,536.8169999999999,539.026,543.15,547.275,551.399,555.524,557.541,561.666,565.79,567.807,571.932,576.056" y="629.517" svg_rhmargin="580.18" style="fill:#171615;font-family:FHEHAC+AdvOTbc475f09;font-size:7.47px;font-style:NORMAL;font-weight:normal;">[32] Fentiman IS. The biology of male breast cancer. Breast 2018;38:132</text>
  <text x="580.252" y="629.517" svg_rhmargin="583.988" style="fill:#171615;font-family:FHEHBD+AdvOTbc475f09+20;font-size:7.47px;font-style:NORMAL;font-weight:normal;">–</text>
  <text x="583.994,588.119" y="629.517" svg_rhmargin="590.136" style="fill:#171615;font-family:FHEHAC+AdvOTbc475f09;font-size:7.47px;font-style:NORMAL;font-weight:normal;">5.</text>
  <text x="345.205,347.611,351.735,355.859,358.265,361.588,363.994,368.118,370.995,374.731,378.855,380.873,387.015,389.309,396.781,398.798,401.1,406.465,410.201,414.325,418.061,421.79699999999997,424.059,427.795,429.812,432.109,438.252,441.988,446.112,450.236,452.254,455.519,459.255,462.52,464.819,468.943,470.96,473.209,476.474,478.88,481.146,484.882,486.899,488.916,491.18,498.651,502.387,504.405,507.66999999999996,510.0,514.513,519.878,525.243,530.6080000000001,532.903,539.045,543.169,545.575,549.311,551.717,553.734,557.859,561.984,564.252,567.517,571.253,574.129,577.006,579.023,582.289,585.165,588.042" y="638.4739999999999" svg_rhmargin="590.059" style="fill:#171615;font-family:FHEHAC+AdvOTbc475f09;font-size:7.47px;font-style:NORMAL;font-weight:normal;">[33] Ibrahim M, Yadav S, Ogunleye F, et al. Male BRCA mutation carriers:</text>
  <text x="361.589,364.854,366.871,368.889,373.013,375.031,378.296,382.032,384.049,386.078,389.343,393.468,397.204,400.08,403.816,407.082,409.487,412.835,415.711,417.729,420.605,423.011,425.029,428.294,431.171,433.186,436.922,441.046,445.171,447.188,450.453,454.189,458.313,461.579,464.844,467.721,469.75,472.626,476.751,480.016,483.281,485.687,488.564,492.688,498.83,500.847,502.856,507.369,514.84,520.205,522.244,527.608,531.344,535.469,538.734,541.999,544.876,546.903,551.027,555.152,559.276,563.401,565.418,569.542,573.667,575.684,579.809,583.933,588.058" y="647.432" svg_rhmargin="590.075" style="fill:#171615;font-family:FHEHAC+AdvOTbc475f09;font-size:7.47px;font-style:NORMAL;font-weight:normal;">clinical characteristics and cancer spectrum. BMC Cancer 2018;18:179.</text>
  <text x="345.205,347.611,351.735,355.859,358.265,361.588,367.341,370.606,374.731,377.518,381.254,383.271,385.965,391.719,395.843,398.72,401.668,403.686,407.81,411.546,414.811,417.541,422.906,427.419,429.436,432.223,436.348,440.084,444.208,447.944,450.647,453.524,458.037,460.054,462.835,466.1,468.50600000000003,471.225,474.961,476.979,478.996,481.77,486.283,491.647,497.012,502.377,506.502,509.264,512.529,516.265,519.141,522.018,524.035,527.301,530.177,533.054,535.851,541.604,543.621,546.027,550.152,552.914,559.056,562.792,564.809,568.074,570.828,574.952,577.829,581.094,584.83,587.706" y="656.389" svg_rhmargin="590.112" style="fill:#171615;font-family:FHEHAC+AdvOTbc475f09;font-size:7.47px;font-style:NORMAL;font-weight:normal;">[34] Deb S, Gorringe KL, Pang JB, et al. BRCA2 carriers with male breast</text>
  <text x="361.589,364.854,368.59,372.714,375.979,379.245,382.122,384.661,387.538,391.662,395.786,401.539,404.049,407.314,409.331,412.596,416.332,420.068,422.474,425.739,429.864,432.393,434.799,438.923,445.065,449.19,453.314,456.19100000000003,458.753,464.894,468.16,470.566,474.69,478.426,480.443,484.179,486.585,488.602,492.727,496.851,498.868,501.438,505.951,513.423,518.788,521.28,526.644,530.38,534.505,537.77,541.035,543.9119999999999,546.449,550.574,554.698,558.823,562.947,564.964,569.089,573.213,575.231,579.355,583.48,587.604" y="665.403" svg_rhmargin="589.621" style="fill:#171615;font-family:FHEHAC+AdvOTbc475f09;font-size:7.47px;font-style:NORMAL;font-weight:normal;">cancer show elevated tumour methylation. BMC Cancer 2017;17:641.</text>
  <text x="345.205,347.611,351.735,355.859,358.265,361.588,367.341,371.466,374.342,377.608,381.733,384.603,388.339,390.356,393.164,398.529,402.264,406.389,410.125,413.002,415.839,421.204,423.221,426.043,429.779,433.904,437.64,439.657,445.799,449.923,452.8,456.536,459.433,465.657,467.674,470.487,473.752,476.158,478.991,482.727,484.744,486.761,489.592,495.345,499.081,501.958,504.364,507.24,509.258,512.523,515.385,518.65,522.386,526.511,529.776,533.041,535.918,538.741,540.758,544.883,547.755,551.491,555.615,559.74,563.864,567.6,570.43,574.166,577.043,579.841,583.965,585.983" y="674.36" svg_rhmargin="590.107" style="fill:#171615;font-family:FHEHAC+AdvOTbc475f09;font-size:7.47px;font-style:NORMAL;font-weight:normal;">[35] Gurzu S, Kadar Z, Sugimura H, et al. Gastric cancer in young vs old</text>
  <text x="361.589,366.953,371.078,377.22,380.956,385.08,387.097,390.833,394.958,397.075,401.2,404.936,407.342,409.434,412.699,416.823,419.229,422.106,424.123,426.214,428.231,434.373,440.515,444.639,448.764,452.888,457.012,459.889" y="683.317" svg_rhmargin="464.013" style="fill:#171615;font-family:FHEHAC+AdvOTbc475f09;font-size:7.47px;font-style:NORMAL;font-weight:normal;">Romanian patients: immunopro</text>
  <text x="464.089" y="683.317" svg_rhmargin="468.213" style="fill:#171615;font-family:FHEHBE+AdvOTbc475f09+fb;font-size:7.47px;font-style:NORMAL;font-weight:normal;">ﬁ</text>
  <text x="468.228,470.245,473.51,475.598,481.351,483.369,485.775,489.9,491.981,495.247,501.388,505.513,509.637,513.373,516.25,518.267,521.144,523.273,527.398,531.523,533.648,539.79,543.526,546.402,550.527,552.544,556.669,558.761,562.497,566.621,570.746,572.82,578.961,582.227,586.425" y="683.317" svg_rhmargin="590.161" style="fill:#171615;font-family:FHEHAC+AdvOTbc475f09;font-size:7.47px;font-style:NORMAL;font-weight:normal;">le with emphasis on maspin and mena</text>
  <text x="361.589,365.713,368.59,372.714,375.12,378.385,380.403,384.528,387.099,389.976,393.241,396.977,400.242,402.648,404.665,408.401,410.418,412.824,416.56,418.577,421.112,426.477,430.601,438.073,440.479,444.215,446.735,450.859,454.984,459.108,463.233,465.25,469.375,473.499,477.623,479.641,483.765,487.89" y="692.274" svg_rhmargin="492.014" style="fill:#171615;font-family:FHEHAC+AdvOTbc475f09;font-size:7.47px;font-style:NORMAL;font-weight:normal;">protein reactivity. APMIS 2015;123:223</text>
  <text x="492.095" y="692.274" svg_rhmargin="495.831" style="fill:#171615;font-family:FHEHBD+AdvOTbc475f09+20;font-size:7.47px;font-style:NORMAL;font-weight:normal;">–</text>
  <text x="495.837,499.962,504.087" y="692.274" svg_rhmargin="506.104" style="fill:#171615;font-family:FHEHAC+AdvOTbc475f09;font-size:7.47px;font-style:NORMAL;font-weight:normal;">33.</text>
  <text x="345.205,347.61,351.735,355.859,358.265,361.588,367.341,371.466,374.342,377.607,381.732,384.603,388.339,390.356,393.221,396.097,400.222,404.346,408.082,410.965,413.37,415.387,418.221,423.587,427.711,430.976,433.853,436.73,440.465,444.59,446.996,449.911,454.035,457.771,460.177,462.583,465.848,468.724,472.849,475.704,479.828,482.234,485.115,487.521,491.645,494.90999999999997,497.756,501.021,504.757,507.163,511.288,515.412,518.677,521.554,525.29,527.696,529.713,533.838,536.757,540.882,542.899,546.164,549.9,552.306,556.431,560.555,563.82,566.697,570.433,572.839,574.856,578.981,581.881,586.006" y="701.232" svg_rhmargin="590.13" style="fill:#171615;font-family:FHEHAC+AdvOTbc475f09;font-size:7.47px;font-style:NORMAL;font-weight:normal;">[36] Gurzu S, Jung I. Aberrant pattern of the cytokeratin 7/cytokeratin 20</text>
  <text x="361.589,363.606,369.748,375.89,380.014,384.139,388.345,392.47,396.594,399.859,403.984,408.108,410.514,414.25,418.374,421.639,425.476,427.494,431.619,435.454,438.719,442.844,444.861,448.985,451.862,455.127,458.469,460.875,464.611,466.628,470.431,474.167,478.291,481.556,485.681,489.875,493.14,496.876,499.753,503.018,505.035,509.16,513.284,519.426,523.162,526.039,529.897,535.651,537.668,540.074,544.199,548.038,552.551,557.916,563.281,567.406,571.281,577.423,581.547,583.953,587.689" y="710.189" svg_rhmargin="590.095" style="fill:#171615;font-family:FHEHAC+AdvOTbc475f09;font-size:7.47px;font-style:NORMAL;font-weight:normal;">immunophenotype in colorectal adenocarcinomas with BRAF muta-</text>
  <text x="361.589,363.995,366.012,370.136,374.261,377.138,379.155,381.713,385.838,389.574,391.979,396.104,400.228,402.245,404.729,410.093,413.359,416.236,418.788,422.913,425.789,429.525,432.79,435.196,437.723,441.847,445.971,450.096,454.22,456.238,460.362,464.486,468.611,470.628,474.753,478.877" y="719.146" svg_rhmargin="483.001" style="fill:#171615;font-family:FHEHAC+AdvOTbc475f09;font-size:7.47px;font-style:NORMAL;font-weight:normal;">tions. Pathol Res Pract 2012;208:163</text>
  <text x="483.081" y="719.146" svg_rhmargin="486.817" style="fill:#171615;font-family:FHEHBD+AdvOTbc475f09+20;font-size:7.47px;font-style:NORMAL;font-weight:normal;">–</text>
  <text x="486.766,490.891" y="719.146" svg_rhmargin="492.908" style="fill:#171615;font-family:FHEHAC+AdvOTbc475f09;font-size:7.47px;font-style:NORMAL;font-weight:normal;">6.</text>
  <text x="85.039,89.272,90.683,93.316,97.381,99.7,102.331,106.396,107.806,109.958,112.649,119.2,123.265,127.824,129.235,133.3,134.71,138.943,143.008,145.587,147.492,151.891,156.291,160.69,165.09,166.995,169.623,174.023,178.422,180.574,184.974,189.373,517.041,522.931,528.821,534.711,536.863,543.414,547.973,550.874,552.285,556.685,560.917,563.3,567.532,571.597,573.008,575.16,579.224,583.624" y="9.870999999999981" svg_rhmargin="590.176" style="fill:#171615;font-family:FHEGPK+AdvOT6e5d2ec0;font-size:7.97px;font-style:NORMAL;font-weight:normal;">Li et al. Medicine (2018) 97:40 www.md-journal.com</text>
  <text x="335.396" y="739.625" svg_rhmargin="339.796" style="fill:#171615;font-family:FHEHPG+AdvOTf94803d4;font-size:7.97px;font-style:NORMAL;font-weight:normal;">7</text>
 </g>
</svg>
